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ABSTRACT
ENGINEERING THE EXTRACELLULAR MATRIX:
A NOVEL APPROACH TO POLYMERIC BIOMATERIALS
SEPTEMBER 1999
ERIC R. WELSH, B.S., UNIVERSITY OF UTAH
M.S., UNIVERSITY OF MASSACHUSETTS AMHERST
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Professor David A. Tirrell
Principles of genetic engineering and recombinant DNA technology were applied to
the modification and microbial synthesis of artificial extracellular matrix proteins, which
were designed for eventual application in vascular prostheses. Proteins were synthesized,
in which the elastin-like pentapeptide (VPGIG) was repeated alone or in a blocky structure
with a cell binding domain derived from the CSS region of fibronectin. To control physical
and mechanical properties, unique amine functionality was added to the termini of these
proteins by the incorporation of lysine-containing fusions. Detailed purification protocols
were developed for the isolation of three CS5-containing proteins having the same primary
sequence, yet distinct lengths, and one CS5-free protein. The success of these protocols
was verified by SDS-PAGE, Western analysis, amino acid analysis, and, in two cases,
NMR spectroscopy. The integrity of the elastin-like sequence was further verified by the
presence of a lower critical solution temperature (LCST).
Reacting the engineered proteins with glutaraldehyde resulted in crosslinked
biomaterials that exhibited improved stability, with respect to solubility, and controllable
mechanical response. The elastic moduli of these biomaterials was found to be inversely
related to the protein masses from which they were derived, and approached modulus
values of native elastin. Approximately, three out of every 4 amines participated in the
crosslinking reaction, which was observed to be complicated one.
V
Measurement of biological properties was limited to the evaluation of substrate
specificity, with respect to cellular adhesion and spreading. Human umbilical vein
endothelial cells (HUVECs) were observed to adhere to crosslinked, CS5-containing
substrates at levels similar to that of fibronectin (FN) and at levels significantly greater than
to the CS5-free control. HUVEC adhesion was found to be independent of blocking
conditions. The binding mechanism did not involve the elastin binding protein, yet was
one in which the CSS domain participated. Human umbilical artery smooth muscle cells
(UASMCs) behaved in the same manner and with an unknown binding mechanism.
Glutaraldehyde reaction products were implicated as participants in a nonspecific binding
mechanism.
Due to the ambiguities introduced by glutaraldehyde, a Zjw-N-hydroxysuccinimidyl
ester of polyethylene glycol was employed as a crosslinking agent. The aqueous reaction
conditions, although controllable to a certain extent, through pH and temperature, proved to
be deleterious in achieving stable networks. HUVEC seeding indicated that this strategy,
or other similar ones, may not alter binding characteristics in a significant manner.
vi
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CHAPTER 1
INTRODUCTION
1.1 Mortality
A brief review of mortality statistics in the United States reveals that diseases of the
cardiovascular system rank high among the leading causes of death, Figure 1 ' . Of the 2.3
million deaths reported in 1996, heart disease and stroke accounted for some 894,265
deaths, representing 38.5%, and rank in the top ten leading causes of death for all age
groups. Contributing to these statistics is the fact that an estimated 58.8 million Americans
have cardiovascular disease, of whom, 50 million, or one-fourth of the adult population,
have hypertension.
Pneumonia/
Influenza
Liver Disease 1.1%
Suicide 1.3%
HIV 1 .4%
Diabetes 2.7%
Accidents 4%
COPD 4.6%
All Other Causes
3.6%
Heart Disease
Stroke 6.9%
Figure 1.1 Leading causes of deaths, U.S., 1996. (2,322,421 total deaths)
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Annual expenditures for health and lost productivity due to cardiovascular diseases
cost the nation billions of dollars. In 1998, an estimated 171.1 billion dollars were spent in
direct costs for hospital care, professional care, and drugs. For the same year, indirect
costs associated with lost earnings due to illness and projected lost earnings due to death
accounted to 25.2 and 77.9 billion dollars, respectively!.
Based on the prevalence and socio-economic costs of cardiovascular diseases,
advances in prevention and intervention are lacking and further understanding and research
are needed at many different levels. Before contributing to such an endeavor, however, a
rudimentary knowledge of both the pathology and physiology of the cardiovascular
system, or specific elements thereof, must be obtained. Since the focus of the work
described herein is centered on the development of materials for vascular grafts, the scope
of discussion will be narrowed to relevant topics and is by no means comprehensive.
1.2 Pathology and Physiology of Arteries
Arteries are vessels through which blood is conducted away from the heart. Large,
elastic arteries, leave the heart and divide into medium-sized, muscular arteries that further
divide into small arteries, then arterioles, and, finally, capillaries, which link the arterial and
venous sides of the circulatory system. Regardless of location, arteries are stratified
structures consisting of three layers or tunics. The intermost layer, or tunica intima,
consists of a cellular lining of endothelial cells (endothehum) that represents the blood
interface, a basement membrane and elastic tissue referred to as the internal elastic lamina.
The tunica media, the second layer, is usually the thickest and consists of smooth muscle
cells distributed helically around the intima and connective tissue. The outermost layer,
known as the tunica adventitia is composed of collagen and elastin fibers, and is physically
connected to the surrounding loose connective tissue and is chemically linked via
microvessels and nerves. The relative composition and thickness of each of these layers is
2
dictated by the distance from the heart and specific arterial function (i.e. conduction or
distribution)2-4.
In 1995, 47,554 deaths were attributed to diseases of the arteries and veins'.
Diseases of the blood vessels are manifested in either obstructions in the lumen, changes in
the vessel wall, or external compression^. Obstructions consist of thrombi or emboli that
restrict or prevent blood flow to distal tissues, resulting in ischemia. Thickening of arterial
walls and consequent loss of elasticity are the main characteristics of a group of diseases
called arteriosclerosis. External stimuli that lead to vessel compression include increased
tissue pressure (edema), torsion, or localized pressure on body parts. A variety of factors,
including diet, exercise, genetic predisposition, stress, and anxiety, contribute to vascular
disease and dysfunction.
Atherosclerosis, one form of arteriosclerosis, is thought to kill more people in the
Western world than any other disease, as it is the first step in a cascade of events that leads
to the degeneration of the cardiovascular system^. The formation of an atherosclerotic
plaque is initiated by an accumulation of cholesterol esters in the subendothelial space by
diapedesis, the translocation of materials between cells, and/or damage to the endothelium.
As lipids accumulate, smooth muscle and other cells proliferate to form a structure that
reduces the elasticity of the vessel wall and that is obstructive to blood flow. The formed
plaque resembles a site of injury and, thus, stimulates the recruitment of macrophages,
smooth muscle cells, and platelets. Further proliferation leads to eventual occlusion of the
lumen and/or the shedding of emboli that clog distal arteries or arterioles.
1.3 Current Intervention
Every year in the United States, there are approximately 560,000 hospitalizations
for diseases of the arteries and veins, resulting in 3.9 million combined hospital days'.
These visits culminate in some 5.44 million inpatient (1996) and 898,000 outpatient
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procedures (1996) annually, representing nearly 9% of all surgical procedures
(6,341,000/71,904,000)6. For the coronary artery alone in 1996, 721,000 procedures to
remove obstructions and insert stents, and 598,000 bypass operations were performed^.
These two strategies (bypass and angioplasty) are also prescribed for peripheral arterial
dysfunction, although patency rates are usually low and a function of location^. The limited
success of available intervention techniques is evident in the mortality statistics, presented
above, and the 159,000 annual amputations (1996) that result from the progression of
peripheral arterial diseases^.
While arteriosclerosis is somewhat reversible, pending changes in diet and exercise
in some people, current intervention to repair hardened or otherwise compromised vessels
consist of reopening the occluded region or replacement of the vessel in question. The first
of these treatments is analogous to roto-rooting conventional plumbing and is achieved by
means of inserting a balloon catheter into the obstructed artery (balloon angioplasty), which
may be rendered partially accessible with plaque vaporization by a laser (laser angioplasty),
and subsequent inflation of the balloon to expand the vessel wall to its original dimensions.
Alternatively, a rotating drill may be used to shave off the plaque to achieve the same result
(catheter artherectomy). Even with the use of stents, a stainless steel device inserted into
the opened vessel to maintain patency, angioplastic techniques are prone to restenosis, the
closure of the vascular lumen'*.
Approximately 550,000 vascular grafts are implanted annually in the United
States^. A majority of these procedures are necessitated by progression of atherosclerosis.
This condition is characterized either by localized regions of vessel dilation (aneurysm), or
by narrowing of the vascular lumen via the deposition of plaques of cholesterol esters,
which results in vessels of reduced capacity to conduct blood. Consequently, distal
ischemia usually ensues with subsequent loss of downstream tissues and eventual
myocardial infarction, if not corrected. Occlusive disease is the most common of the two
atherosclerotic conditions and is most prevalent in the aorto-iliac and femoral-popliteal-tibial
arterial systems (Figure 1.2)8.
Coronary artery
Aorta
Common iliac artery
Femoral artery
Popliteal artery
Anterior tibial artery
Posterior tibial artery
Figure 1.2 Schematic of arterial system with vessels affected by atherosclerosis labeled.
Grafts are classified according to the source from which they are derived.
Specifically, grafts from biological sources are termed autografts, if from the same
individual, allografts, if from the same species, and xenografts, if from a different species.
These are distinguished from synthetic grafts, which have been derived from a number of
different polymers.
The history of vascular grafts reveals the use of a wide range of graft sources and
materials. During the first half of this century, biologic alio- and autografts were used with
little success, as issues of immune response and preservation techniques were not well
understood '0. Vinyon-N cloth, a nylon-based fabric, the first synthetic graft material, was
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introduced by Voorhees et. al. in 1952, and was succeeded by a wide range of synthet
fabrics. Subsequent biologic and physical evaluation of many materials lead to the
selection of poly(ethlylene terepthalate) (Dacron) and expanded polytetrafluoroethyl
(ePTFE). These two materials have been the accepted synthetic grafting conduits for
thirty years^.
In addition to the synthetic materials evaluated, biologic grafts have also been
explored. Both autogenous arterial and venous grafts have been found to be acceptable,
but suffer from the obvious restriction of limited supply 8. 10. Allografts from
glutaraldehyde tanned human umbilical vein with Dacron supports, aldehyde treated
cadaveric grafts, and cryopreserved cadaveric saphenous veins have met limited success,
and ultimately fail due to immune rejection, infection, and aneurysm formation.
Xenografts, such as dialdehyde-tanned'
' and negatively charged glutaraldehyde-tanned
bovine grafts, are similarly prone to rejection and late aneurysmal dilatation^^iO.
In spite of nearly four decades of research, there is currently no widely accepted
small diameter (<4-6 mm) synthetic graft. While Dacron and ePTFE have proven to be
useful in vessels with high flow rates and low resistance, substitutes for the smaller, high
distal resistance and low-flow muscular arteries are still lacking. The best graft source for
these arteries is the autogenous saphenous vein and, in the case of coronary artery bypass,
the internal mammary artery, but, due to obvious reasons, are available in limited
supply8''2
In order to engineer viable small diameter grafts, it is instructive to examine the
physical requirements of these implants. Increased patency rates have been correlated to
reduced compliance mismatch between the graft and native vessel j\^q relatively non-
compliant synthetic vessels not only disrupt the dilatory and subsequent conduction
mechanisms inherent to arterial walls, but also significantly disrupt laminar flow in the
anastomotic regions. Non-laminar flow is manifested by regions of turbulence and
concomitant regions of hemostasis. Physiological response to such hemodynamic trauma
is manifested in thrombus formation and anastomotic pseudointimal hyperplasia, conditions
that severely limit the patency of the graft. Also, grafts should have sufficient crush
strength and flexibiiity to withstand flexion in cross-joint applications. Surface porosity is
necessarily balanced between the need for microvascularization of the graft and containment
of blood loss. Finally, mechanical integrity should be maintained in the pulsatile stress and
biologic environment to avoid aneurysmal and pseudoaneurysmal distensions.
In addition to these mechanical requirements, biological compatibility is paramount
to graft success. The physiological events that result in eventual graft failure are initiated
with protein adsorption to the luminal surface J'^- 15. Preferential adsorption of the blood-
borne protein fibrinogen selectively sequesters platelets, which subsequently attach to the
fibrinogen-rich regions and become activated. Platelet activation involves sequestration of
yet more platelets and the secretion of the enzyme thrombin, which converts fibrinogen to
fibrin. Thus, most synthetic grafts attain a lining or pseudointima of fibrin. Leukocytes
(monocytes / macrophages) and erythrocytes are recruited and adhere to the fibrous
structure, resulting in thrombus formadon. Furthermore, activated platelets release growth
factors like platelet-derived growth factor (PDGF), a smooth muscle cell (SMC)
chemotaxin and mitogen
,
and produce the prostaglandins thromboxane \, a platelet
aggregator and vasoconstrictor, and its antagonist, prostacyclin. This cascade of events
leads to the formation of the neointima and neointimal hyperplasia. Continued proliferation
of SMCs and deposiUon of extracellular matrix proteins by the same cells characterize the
condifions of anastomodc neointimal hyperplasia. These events, taken together or alone,
constitute a highly unhealthy condition in which the body is in a confinual state of graft
rejecfion. Thromboses are not only occlusive but confinually shed micro-emboli that
potentially clog distal vessels. Neoindmal hyperplasia and neoindmal thickening result in
luminal narrowing and occluded vessels, condidons for which the atherosclerotic vessel
was replaced in the first place, and constitute graft failure^- 14-16,
The structure-function relationship evident in native vessels define the features
needed in synthetic grafts. Surface chemistry that leads to a confluent endothelial layer is
essential. The endothelium not only controls diffusion of blood-borne nutrients across the
intimal barrier to surrounding tissues, but regulates platelet adhesion to the luminal
surface 14. A functional endothelial surface controls thrombotic events by balancing fibrin
elimination (fibrinolysis) via enzymes, such as tissue plasminogen activator (t-PA), with
fibrinogen deposition, and is able to regulate platelet adsorption with prostacyclin-^- '4. The
importance of the endothelium is evident in the improved patency of conventional synthetic
grafts onto which autologous endothelial cells are seeded '7 or sodded 18. Also essential are
the extracellular proteins elastin and collagen and their respective composition, function,
and spatial orientation. An elastic lamina confers diffusional properties via fenestrations,
mechanical flexibility, and serves as a sink for storage of elastic energy during cardiac
systole 19. However, collagen is the major load bearing constituent and is required for
mechanical integrity and to provide a matrix for SMC function. Thus, an ideal model
structure would be one with a confluent endothelium on concentric layers of elastin and
collagen lattices having sufficient mechanical flexibility and strength, as well as offering an
environment for SMC proliferation and differentiation, and interaction with the extra-
arterial environment.
1 .4 Tissue Engineering
Tissue loss and organ failure affect millions of Americans each year. Nearly 8
million surgical procedures are performed annually in the United States at a cost of
approximately $400 billion and require an estimated 40-90 million hospital days^O.
Restoration of these essential organs and tissues, or their respective functions, is currently
accomplished by transplantation, surgical reconstruction, use of mechanical devices, and
direct delivery of organ products. While these treatments extend the lives of many patients
8
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and have been employed with cUnical success, they suffer from the lack of adequati
donors, immune response that leads to ultimate rejection of the donated organ or tissue, and
failure to reconstitute organ function.
The field of tissue engineering applies the principles of biology and engineering to
the development of functional tissue substitutes. Current strategies for regeneration of
tissue function include the replacement of damaged cells with isolated cells or cell
substitutes, the administration of tissue growth factors and signal molecules, and the
implantation of cell-containing synthetic or biologic matrices or membranes2(^. These
approaches restore physiological processes that have been lost or compromised, by
providing biochemical stimuli through chemical agents or physical templates that serve to
guide biological response, or by blocking an undesired biological response21. Tissue
engineers have applied these strategies alone or in combination to the treatment of many
tissue-related diseases22-25
The success of many tissue equivalents depends on the biocompatibility of the
implanted material. In the past, biological compatibility was characterized by a state of
physiological inactivity or, in other words, inertness. Current criteria call for implant
materials that play a more active biological role. Specifically, biocompatibility still requires
a state of physiological inactivity with respect to eliciting an immune response, but, unlike
its inert antecedent, the material should be resorbable and should interact with implanted or
native cells to control cellular adhesion, motility, growth, and phenotypic differentiation, as
desired. Ideally, the rate of physiological resorption matches the rate of natural tissue
replacement and subsequent transfer of biological processes and physical support. Devices
prepared from such materials should be readily processable and sterilizable for clinical
applications. Polymers, either synthetic or biologic, have the almost unique ability to fulfill
these criteria and have been designed, synthesized, processed, and applied to many tissue
engineering applications^^'^?
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1.5 Engineered Polypeptides
Polypeptides obtained via genetic engineering result in polymers of well-defined
molecular architectures. Structural definition is obtained on three levels: first, chain length,
which is dictated by the length of the DNA template from which the polypeptide is derived;
second, monomer sequence, which is encoded at the genetic level; and, finally,
stereochemistry, which is fixed by the biosynthetic machinery. In theory, since both the
length and sequence (codons) of the artificial gene (DNA) are determined by the sequence
and number of amino acids desired in the final polypeptide, proteins may be engineered to
have a wide variety of sequences and lengths. Thus, in most cases, it is possible to exploit
the high fidelity of the biosynthetic mechanism, where the overall error rate in protein
synthesis is approximately 5 x 10'^ per codon2«, to achieve polymers, in this case
polypeptides (proteins) of well defined molecular architectures.
In addition to the primary molecular architectures, higher order molecular
architectures are also achievable. By the judicious choice of primary sequences from
nature, which form well-defined secondary (a-helix, (3-sheet, and etc.), tertiary (anti-
parallel sheets, multiple helices, enzymes and etc.), and ternary (fibers and crystals)
structures, it is possible to exploit nature at higher levels of molecular assembly 29-38
Thus, nature and evolution provide not only a high-fidelity biosynthetic mechanism, but
also a library of amino-acid sequences with inherent assembly and function (i.e. enzymes
and antibodies) information.
1.6 Artificial Extracellular Matrix Proteins
Owing to the lack of materials suited for small-diameter vascular grafts, efforts have
been focused on the design and synthesis of polymers having well-controlled properties.
Ideally, such a material would promote or sustain endothelialization, a property paramount
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to the patency of vascular prostheses, and would have elastic characteristics. With this end
in mind, Panitch designed and synthesized alternating diblock copolypeptides, in which
one block consisted of an endothelial cell binding domain derived from fibronectin and the
other block was an elastin analog39.
The adhesive block was derived from the alternatively spliced type HI connecting
segment of fibronectin known as the CS5 domain. Humphries et al. have shown that the
minimal adhesion sequence of the CSS domain is the tetrapeptide Arg-Glu-Asp-Val
(REDV)40,41^ and have elucidated that recognition and adhesion is through the a^p,
integrin, a cell-surface receptor42 Hubbell and coworkers have confirmed the endothelial
cell specificity of this peptide, relative to other cell types, and have also reported optimal
surface densities of the binding ligand for endothelial cell adhesion, as well as ligand
binding sites per cell23.43
An elastin analog was chosen for the second domain. Based on extensive work of
Urry and coworkers, a model peptide was designed with the amino acid sequence Val-Pro-
Gly-Ile-Gly (VPGIG), which is analogous to the pentapeptide VPGVG that is repeated
multiple times in mammalian elastin'*'*. The substitution of isoleucine for valine in the
fourth position was made to decrease the lower critical solution temperature (LCST) below
physiological temperature (37°C), thereby facilitating processing at ambient conditions and
decreasing solubility at 37°C. This substitution resulted in a decrease in LCST from 24°C'*5
to 12-13.5°C39, close to the value predicted by Urry et al.46. This result suggests that
polymers of VPGIG undergo a conformational transition similar to that of native elastin
peptides. That is, to optimize intramolecular, hydrophobic interactions, this transition is
characterized by the formation of a helical series of (3-turns, constituting a motif known as
the P-spiral, which is considered the origin of the entropic, elastomeric properties of
elastin47,48.
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Two polypeptides were synthesized having a two-fold difference in adhesion hgand
(CSS) density, Figure 1.3. In contrast to the results reported by Nicol et al.49, where the
minimal adhesion peptide REDV was copolymerized with VPGVG, at various
concentrations, Panitch et al. observed endothelial cell adhesion and spreading on CS5-
containing elastin analogs^O. Specifically, substrates coated with la were shown to
support similar levels of attachment as the control substrate fibronectin, while adhesion to
lb was approximately four-fold lower.
MGrLDGEEIOTGHTPREDVnYHT YPnrvPnTn^ VP] t p i ^
MGrLDGEEIOIGHIPREDVDYHT YPGrVPGTn^^ VP] T f i b
Figure 1.3. Elastin analogs containing the CS5 domain from fibronectin (underlined) with
the minimal adhesion domain REDV (bold).
These preliminary artificial extracellular matrix proteins will serve as the basis for
subsequent investigations into the control of physical and mechanical properties. In spite
of the sub-physiological transition temperature, approximately 75% of films cast from la-
fa solubilize in aqueous media within 3 hours, a time-frame much shorter than what might
be required for application as a stable vascular graft material. This solubility issue also
makes the determination of mechanical properties under in vitro conditions nearly
impossible. Thus, the control and measurement of physical and mechanical properties, and
their effect on biological properties will constitute the bulk of the discussion that follows.
1 .7 Dissertation Plan
The following is a distillation of two years of research on elastin-like artificial
extracellular matrix proteins. Not discussed are the results of two years of investigations
into artificial collagen analogs, work that served as a basis for acquiring skills in all phases
of artificial gene design, manipulation, and expression. Unfortunately, this work did not
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yield much else, except for a clear understanding that some artificial genes, no matter how
well-designed, just don't work, and that there comes a time to change focus.
Chapter 2 describes the design, synthesis, purification and evaluation of amine-
containing elastin analogs, based on la, above. Evaluation includes analytical,
spectroscopic, physical, and mechanical measurements.
Investigations into the biological properties of cross-linked elastin analogs, with
respect to cellular adhesion, are described in Chapter 3. The design, synthesis, and
purification of an amine-containing poly(VPGIG) control protein is also described.
The final chapter presents the development of composite gels that are based on the
reaction of macromonomers of polyethylene glycol (PEG) and an engineered elastin
analog.
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CHAPTER 2
AMINE-CONTAINING ELASTIN ANALOGS: PHYSICAL PROPERTIES
2.1 Introduction
Genetic engineering provides a tool for the design and synthesis of polypeptides
having pre-determined and precisely-controlled molecular architectures. Specifically, the
primary, or amino acid, sequence of a polypeptide and its size may be controlled by
varying the order and length of the encoding DNA. With nature as a template, this strategy
has been employed in the Tirrell lab to synthesize proteins with well-defined higher-order
structures' -8. unique gellation properties^, catalytic activity, precursors to smectic-phase
liquid crystals'^, and analogs to the extracellular matrix protein elastin^'.
With the work of Urry et al. in mindi2,l3^ elastin analogs were microbially
synthesized with varying densities of the CSS region of the alternatively-spliced type EI
connecting segment (III CS) of human fibronectin'^, which contains the minimal
endothelial cell-binding ligand Arginine-Glutamic Acid-Aspartic Acid-Valine (REDV) 15-17.
Unlike the work of Nicol'^, Panitch et al. demonstrated endothelial cell adhesion and
spreading on films of the elastin analog containing the REDV domain' l. In spite of the fact
that these analogs were designed to exhibit a lower critical solution temperature (LCST)
near 10°C and, consequendy, expected to have decreased solubility near room and
physiological temperatures, substanUal solubilization was observed up to a plateau level,
prior to cell-adhesion assays. The present work, thus, focuses on stabilizing the solubility
of these analogs, by means of creating network structures through chemical crosslinks, and
assessing endothelial cell adhesion to the resultant material.
To avoid any disturbances in the conformation or presentation of the critical cell-
binding domain (REDV), an amine-specific cross-linking chemistry was chosen. Although
Y-irradiation has proven to be a useful cross-linking method for elastin-like materials' 9, a
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source was not available. Based on the endothelial cell binding results of Panitch et al. 1 1
,
the existing primary sequence la (Figure 2.1), was modified at the genetic level to
incorporate lysine residues (K) at the termini of the protein, lb. Two shorter analogs of
the same primary sequence were similarly modified, Ic-d. Incorporation of these residues
imparts a primary amine functionality of four; three from the lysine side chains and one
from the amino termini. With a prudent choice of chemical agent, the resultant protein is
thus susceptible to cross-linking reactions specific to the added amine functionality.
MG[LDCS5G(VPGIG)2oVP]5LE la
MMASMTGGQQMGRKTMG[LDCS5G(VPGIG)2oVPl^LEKAAKLE Ib-d
Figure 2. 1 CS5-containing elastin analogs with (b-d) and without (a) lysine (K) where
CSS = -GEEIQIGHIPREDVDYHLYP- (x=5,3,l for b, c and d, respectively).
'
The following discussion describes the synthesis, purification and characterization
of amine-containing elastin analogs Ib-d. Evaluation includes analytical, spectroscopic,
physical, and mechanical measurements.
2.2 Experimental Section: Materials and Methods
2.2.1 General Methods
Standard molecular biological techniques were used for DNA manipulations,
bacterial growth, electrophoresis, and Western blotting, as prescribed by well-defined
protocols^O. Large scale fermentations were achieved with New Brunswick Model MF-
214 (10-12 L) and MPP-80 fermentors. A Bruker AMX 500 MHz spectrometer was used
to obtain '^C-NMR spectra, and a Bruker Avance 600 MHz spectrometer was used for 'H,
COSY, TOCSY, and HSQC spectra. Amino acid analyses were performed by either the
Molecular and Cellular Biology Protein Chemistry Core Facihty at the University of
Massachusetts Amherst or New York State Center for Advanced Technology at Cornell
University. A modified Instron test machine (Model 1 123) was used for tensile tests.
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Restriction and modifying enzymes used in genetic manipulations were obtained from New
England Biolabs (NEB), Beverly, MA.
2.2.2 Design and Cloning of Lysine Linkers
The expression vector pET28ap was previously modified by deletion of the
polycloning site between the Ncol and Xhol restriction sites of pET28a (Novagen,
Milwaukee, WI) and insertion of an 18-base pair linker into which elastin analogs were
cloned '4. To obtain elastin analogs of three distinct molecular weights, plasmids labeled
pET28ap-[(REDV)ELj5, pET28ap-[(REDV)ELj3, and pET28ap-[(REDV)ELJ„ were
prepared from AP (Alyssa Panitch) Box 101 glycerol frozen stock numbers 14, 43, and
25, respectively. In this labeling scheme, REDV is equivalent to the entire CSS region of
fibronectin and EL represents five repeats of the pentapeptide VPGIG.
Oligonucleotides were designed to encode a total of three lysine residues at the
termini of the artificial elastin analogs (i.e. [(REDV)EL4]^, for x=l, 3, and 5), by insertion
into restriction sites at the 5'- and 3'-ends of a given gene. Lysine-encoding linkers 2a and
2b were intended for the unique Ncol site at the 5' -end of each gene, while linker 2c was
designed for the unique Xhol site at the 3 '-end of each gene (Figure 2.2). Henceforth, and
consistent with nomenclature used in cloning libraries, linkers 2a, 2b, and 2c shall be
referred to as NK, T7K, and CK.
Oligonucleotides were obtained from Genosys (The Woodlands, TX). Crude
oligonucleotides were resuspended in 10 mM TE buffer (10 mM Tris-HCl, 1.0 mM EDTA,
pH 8.0) at a concentration of 0.1 mM. A 100 ^il annealing solution (100 mM NaCl, 20
mM MgCl2) containing 6 |ig of each of the complementary oligonucleotides was heated to
near boiling and allowed to cool slowly to room temperature. Annealed oligonucleotides
were ethanol precipitated (0.1 volumes 3.0 M NaOAc, pH 5.2, 2 volumes 100% ethanol,
15 minute incubation at -80°C, 30 minute centrifugation, 2 volumes 70% ethanol wash via
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5 minute centrifugation), dried and resuspended in a 50 ^il phosphorylation reaction
volume, which consisted of 1 x T4 ligase buffer (NEB) and 0.5 ^il T4 polynucleotide
kinase (NEB). The reaction was allowed to proceed at 37°C for 1 hour, after which a
phenolxhloroform (1:1) extraction was performed to remove the kinase. Oligonucleotides
were concentrated via ethanol precipitation, resuspended in 10 mM Tris, pH 8.0, and
quantified with standard DNA markers via polyacrylamide gel electrophoresis (PAGE) in
TBE buffer (0.089 M Tris-borate, pH 8.3, 2 mM EDTA).
Afcd n=qL
1 i
C ATG GCT AAA GC
CGA TTT CGG TAG 2a
Met Ala Lys Ala Met
Ncol I BsiiHI
i
i
C ATG ATG GCT AGC ATG ACT GGT GGA CAG CAA ATG GGT CGC AAA AC
TAG CGA TCG TAG TGA CCA GCT GTC GTT TAG CCA GCG TTT TGG TAG
Met Met Ala Ser Met Thr Gly Gly Gin Gin Met Gly Arg Lys Thr Met
\ \
TC GAG AAA GCT GCT AAA C
C TTT CGA CGA TTT GAG CT
Glu Lys Ala Ala Lys Leu Glu
Figure 2.2 Lysine-encoding oligonucleotide linkers.
2b
2c
Vector pET28ap was isolated by commercially available, chromatographic methods
(QIAprep®, Qiagen, Valencia, CA) or by an alternate alkaline lysis method. Briefly, this
method is as follows: 1) 3-5 ml of saturated culture is centrifuged at 13,000 rpm for 2
minutes; 2) pellet is resuspended in 200 |il GTE buffer (50 mM glucose, 25 mM Tris-HCl,
pH 8.0, 1.0 mM EDTA) with freshly added RNAse (0.04 mg/ml); 3) cells are lysed with
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200 ul 1 % SDS-0.2 M NaOH and gentle inversion, followed by a 5 minute incubation on
ice; 4) extraneous materials are precipitated via addition of 200 \i\ 3.0 M NaOAc pH 4.8,
tube inversion, 5-15 minute incubation on ice, and 20 minute centrifugation at 13,000 rpm;
5) supernatant is extracted with 500 ^il phenolxhloroform (1: 1), reserving aqueous layer;
6) plasmid DNA is precipitated via the addition of 500 ^il isopropanol, a 30 minute
incubation at -20°C, and a 30 minute centrifugation (13,000 rpm, 4°C); 7) supernatant is
quickly removed and DNA pellet is resuspended in 100 |il ddH^; 8) final precipitation is
achieved with 50 ^1 25% PEG 8,000-2.5 M NaCl and centrifugation (13,000 rpm, 30
minutes, 4°C); 9) the almost-invisible pellet is resuspended in either 10 mM Tris-HCl pH
7.6-8.0 or ddH20.
Isolated vector was linearized with the appropriate restriction enzyme and
dephosphorylated with calf intestinal alkaline phosphatase, according to the supplier's
recommendations (NEB). Linearized vector was isolated and quantified via agarose gel
electrophoresis in TBE and excision of the appropriate band from the gel, from which the
DNA was purified with a kit from Qiagen (QIAex II®). Ligation of insert into vector was
most readily achieved by adding a given amount of linearized vector to a 1 5 |a.l reaction
mixture of 1 x T4 ligase buffer, heating to 65°C for 5 minutes, followed by a 5 minute
incubation on ice, and addition of a corresponding quantity of insert and T4 DNA ligase.
The reaction is then allowed to warm to room temperature slowly overnight.
Half of a given ligation mixture was used to transform Escherichia coli strain
DH5aF' or BL21(DE3)pLysS (Novagen), for cloning or expression, respectively .
Transformed colonies are screened for insert via the alkaline lysis mini-prep method,
described above, after growth in rich, 2xYT medium (16 g casein hydrolysate, 10 g yeast
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extract, 5 g NaCl per liter) under antibiotic selectivity (34 |ig/ml kanamycin, SIGMA, St.
Louis, MO). Presence and fidelity of linker were confirmed via restriction mapping and
sequencing via the Sanger method21 using a Sequenase 2.0 kit from Amersham Life
Sciences (Arlington Heights, IL). The T7-promoter and TV-terminator primers (Novagen)
were used for sequencing the 5'- and 3'-ends of the gene, respectively. Verified genetic
constructs in the expression host were labeled as BL21(DE3)pLysS-
pET28apXK[CS5(EL)2o]yCK, where XK is either the NK or T7K linker, y is the number
of CS5-EL cassettes, and EL represents the pentapeptide VPGIG.
2.2.3 Fermentation and Protein Expression
Bacterial cultures were maintained under antibiotic selection in all stages of growth
and were grown from a single colony picked from a freshly streaked plate. Single colonies
were used to inoculate 5 ml Luria-Bertani (LB, 10 g casein hydrolysate, 10 g NaCl, 5 g
yeast extract, 1.0 ml 1 M NaOH per liter) and grown to near saturation (8-16 hours).
Subsequent LB cultures were started using a 100-fold dilution of inoculum volume, i.e. 5
mililiters of saturated culture was used to inoculate a 500 ml culture. Batch cultures of
volumes of 1, 12, or 36 liters were allowed to grow at 37°C, under aerated conditions, to
an optical density range of 0.8-1.5, as determined by optical absorbance measured at 600
nm (ODgoo). Target protein expression was induced with the addition of 0. 1 M P-isopropyl
thigalactoside (IPTG, CalBiochem, La JoUa, CA) to a final concentration of 1 .0 mM.
Expression was allowed to continue for 4-6 hours, during which time the optical density
plateaued in the range of 2.5 < OD^oo< 3.5. Cells were harvested via centrifugation
(2,500g, 20 minutes, 4°C). Induction was confirmed by SDS-polyacrylamide gel
electrophoresis (PAGE) and Western blot analyses, where a T7-tag® antibody HRP-
conjugate (Novagen) was used in the Western blots.
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2.2.4 Purification of T7K(CS5(VPGIG)2o)5CK and T7K(CS5(VPGIG)2o)3CK
Harvested cell pellet was resuspended in 3 volumes of TEN buffer (10 mM Tris-
HCl, pH 8.0, 1 mM EDTA, 0.1 M NaCl], frozen, and thawed. To the thawed whole-cell
lysate, phenylmethylsulfonyl flouride (PMSF, SIGMA) (ImM), MgCl2 (5 mM), RNAse
(10 \Lg/m\), and DNAse (10 jig/ml) were added and allowed to incubate at 37° for several
hours. Target protein was partitioned to the pellet fraction via centrifugation (20,100g, 60
min., 25°C) and was successively extracted from this pellet at low temperature (4°C) with
5.0 M urea and sterile water. The resultant extracts were dialyzed against cold, distilled
water in the presence of an antimicrobial agent (Thimerosal, SIGMA) to remove residual
salts. Centrifugation below the LCST (20,100g, 60 min., 2°C) resulted in a supernatant
enriched in the target protein. Further enrichment was achieved by successive
centrifugation at temperatures below and above the LCST of the target protein (10-15°C).
Yields were in the range of 150-180 mg/L culture. Purity was assessed qualitatively via
SDS-PAGE, and quantitatively by amino acid analysis and NMR.
2.2.5 Purification of T7K(CS5(VPGIG)2o),CK
The cell pellet was treated as above and the target protein was found to partition into
the soluble fraction of the whole cell lysate (WCL). Two successive centrifugation steps
(22,100g, 60 minutes, 4°C) were performed to obtain a clear supernatant. The supernatant
pH was then adjusted to 5.0 with 1.0 N HCl and allowed to incubate at room temperature
for 1 hour. The turbid solution was centrifuged (22,100g, 30 minutes, 4°C), from which
the supernatant was retained and pH adjusted again to 5.0. After overnight storage at 4°C,
the centrifugation process was repeated, reserving the supernatant. This cycle was repeated
until no precipitate formed at 4°C, pH 5.0; usually 3 cycles were sufficient. The resultant
supernatant was dialyzed against cold, distilled water in the presence of Thimerosal, to
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remove residual salts. The dialysate was then centrifuged below the LCST (20,100g, 60
min., 2°C), reserving the supernatant, which was then warmed to room temperature.
Centrifugation of the turbid solution (10,400g, 30 minutes, 20°C) yielded a pellet enriched
in protein coacervate. Based on one 12-L fermentation, a yield of 100 mg/L of culture
obtained. Purity was assessed qualitatively via SDS-PAGE, and quantitatively by i
acid analysis.
was
ammo
2.2.6 Radiolabeling T7K(CS5(VPGIG)2o)5CK
A 1 L culture was grown in M9 minimal medium containing antibiotics, as above,
and all essential amino acids. At an optical density of 0.8/ml, the culture was induced with
IPTG, as before. Five minutes later, 1000 |iCi of ^H-glycine (DuPont NEN Research,
Boston, MA) was added to the culture. Radiolabeling was verified by SDS-PAGE and
autoradiography of the resultant, dried gel. The target protein, now radiolabeled, was
purified, as above, with a yield of 22 mg/L for lb and 44 mg/L for Ic .
2.2.7 Film Casting
For solubilization assays, radiolabeled (4 mg) and non-labeled lb (125 mg) were
dissolved in 10 ml of sterile, cold water. The aqueous solution was cast on glass, which
was treated according to the manufacturer's directions with SurfaSil'"^ (Pierce, Rockford,
IL), resulting in a transparent film, after the solvent was allowed to evaporate at 4°C
(incoherent, flawed films were produced when cast at temperatures above the LCST).
Using a square grid as a template, 9 mm squares were cut from the film with scissors. For
similar assays with Ic, 100 \i\ of a 100 mg/ml (98 mg non-labeled + 2 mg labeled)
aqueous solution was cast on round, glass coverslips (18 mm diameter), and allowed to
dry at 4°C. Prior to solution crosslinking, the films were subjected to a relative humidity of
98% in an enclosed environment at 25°C (super-saturated CuSO^ solution). This annealing
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step is necessary to produce coherent films that remain insoluble in the crosslinking
solution for sufficient time to allow the reaction to occur. Glutaraldehyde (GTA) (Aldrich,
Milwaukee, WI) was dispersed in phosphate-buffered-saline (PBS), pH 7.4, immediately
prior to use. Vapor-phase crosslinking was carried out without the humidity annealing step
in an enclosed chamber at 25°C over a 12.5% aqueous GTA solution. After crosslinking,
films were exposed to solutions of 0.1-0.2 wt.% 5,5-dimethyl-l,3-cyclohexanedione
(Dimedone) (Aldrich), to neutralize any unreacted GTA22,23
For tensile specimens, transparent films of uniform thickness and topology were
obtained by casting protein solutions in polished aluminum molds, measuring 2.5" x 2.5" x
0.06". Lyophilized protein was resuspended in dimethyl sulfoxide (DMSO) at a
concentration of 100 mg/ml and degassed, prior to casting and drying, until tack-free, in
vacuo at 50°C for 2 hours . The dried film and mold were then transferred to a shelf in an
enclosed chamber that contained a pool (20 ml) of 12.5% glutaraldehyde solution. Vapor
phase cross-linking was carried out for 1 8 hours at room temperature, after which it was
observed that the films had become opaque, tanned and swollen. Subsequent films were
then treated with glutaraldehyde solution (10 mM in 1 x PBS, pH 7.4) for 2 hours at room
temperature. Films were then exposed to 0.2 wt.% dimedone in IxPBS, pH 7.4 for 24
hours at room temperature. While still in the mold, 1.0 cm wide strips were cut from the
cross-linked films with a scalpel and straight-edge. Samples were stored in sterile IxPBS,
pH 7.4 at 4°C, prior to mechanical evaluation.
2.2.8 Solubilization Assays
In both solution and vapor-phase crosslinking the first two 24 hour washes were
conducted at 25°C, while washes 3-5 were conducted at 4°C. The 5th wash was
continually agitated with a rotary mixer. Washes consisted of 1 ml of sterile-filtered PBS,
pH 7.4, and were isolated in separate scintillation vials with a micropipette. Prior to
removal of each wash solution, samples were vortexed at high speed for 10 sec. The final
25
wash, or aliquot 6, is obtained by hydrolyzing any remaining, insoluble protein with 0.5
ml of 6.0 M HCl, at 70°C for 48 hours, followed by neutralization to a phenalpthalein
endpoint with 6.0 M NaOH. Aqueous scintillation cocktails were produced by the addition
of 3 ml ScintiSafe Plus™ 50% (Fisher Scientific, Pittsburgh, PA), followed by vigorous
mixing. Scintillation counting was performed in a Beckman LS 1800 automated counter.
The percent of solubilized protein, at each wash, was determined by dividing the measured
counts of a given wash by the total counts of all washes for that same sample. Samples
were prepared in triplicate and reported values are averages, where error is given as the
standard deviation. Error was propagated through all calculations using standard
methods24.
2.2.9 Tensile Testing
Protein strips were measured with vernier calipers and a micrometer, to assess
cross-sectional area, then mounted in aluminum grips with a filter paper spacer, and tensile
tested in a simulated physiological environment (IxPBS, pH 7.4, 37°C). Samples were
allowed to equilibrate in the buffer, after mounting, for 10-15 minutes, before testing at a
strain rate equal to 10% of the gauge length per minute. Gauge lengths of 12-25.4 mm
were used, depending on sample condition. A minimum of three samples of each protein
was evaluated. Reported values are averages, where error is given as the standard
deviation.
2.2.10 LCST Determination
Lyophilized protein was resuspended in sterile, ddHjO and introduced into a 3 ml
quartz cuvette having a 1 cm path length. Samples were continuously stirred, while the
temperature was scanned under control of a peltier temperature module. The percent
transmission at 300 nm was continuously monitored by a Jasco 715 spectropolarimeter .
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2.2. 1 1 £-Amine Titration
Samples cross-linked with GTA, consisting of 10 mg of protein, were immediately
exposed to 1.0 ml NaBH, (1.2 mg/ml in PBS, pH 7.4, 1 hour), to reduce hydrolyzable
Schiff base products. Reacted films and controls, to which no reducing agent was added,
were immersed in 1
.0 ml 4% (w/v) NaHCO,, and placed in a boiling water bath for 3
minutes. To the warm solutions were added 900 pd of water and 100 yd 5% 2,4,6-
trinitrobenzene sulfonic acid (TNBS) (SIGMA). The reaction proceeded for 2 hours at
40°C under constant agitation. Proteins were then hydrolyzed overnight at 75°C with the
addition of 3.0 ml 12.0 N HCl. Cooled reactions were then extracted twice with 5 ml
aliquots of diethyl ether, to remove residual TNBS and a-amino trinitrophenyl amino
acids. Extracted mixtures were heated for 1 hour at 75°C, to remove residual ether, and
were diluted two-fold with water. A blank was prepared with the same quantity of protein,
where the acid was added prior to the addition of TNBS. Peak absorbance was measured
in the range of 330-360 nm, and concentrations were calculated using the molar absorption
coefficient of e-trinitrophenyl lysine (£34^ = 14,600 mol '-cm ')25,26 fixation index
was determined from the results of the above assay and defined as^^
Fixation index (%) =
[(TNBS reactive amine )^„„,, - (TNBS reactive amine ),,,]
^^^^
(TNBS reactive amine ),„„,^„,
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2.3 Results and Discussion
2.3.1 Protein Expression: New Elastin Analogs
Expression of the amine-containing elastin analogs Ib-d is discernible from
constitutive protein expression. Examination of whole cell lysates, 2-5 hours after
induction with IPTG, reveals significant accumulation of proteins near the expected
of 59.2, 36.6, and 14.0 kDa for lb, Ic, and Id, respectively (Figure 2.3).
1 2 3 4 5
29 ^ «
12 3 4
Figure 2.3 12 % SDS-PAGE expression gels of amine-containing elastin analogs. Gel a:
whole cell lysate before (lanes 2 and 4) and 5 hours after induction (lanes 3 and 5) for
proteins lb and Ic, respectively. Gel b: whole cell lysate before (lane 2), 2 hours (lane 3),
and 4 hours after induction for protein Id. In both gels, lane 1 contains standards having
the indicated molecular weights in kDa.
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2.3.2 Purification and Yield
Of the 1850 distinct kinds of proteins expressed in E. colfl^, repeatable protocols
have been developed to purify the target proteins. Paramount to these protocols are the
solubility characteristics of the proteins. Specifically, the longer constructs lb and Ic
partition into the insoluble fraction of the whole cell lysate, from which they are readily
extracted with urea and cold water. Protein Id remains in the soluble fraction of the whole
cell lysate and remains soluble at pH 5.0, where most other proteins precipitate out of
solution. In both cases, however, final enrichment of target protein is achieved by removal
of insoluble contaminants at temperatures below the LCST of Ib-d, followed by
coacervate formation above the LCST. Due the association of these relatively hydrophobic
proteins with contaminating proteins, which, from the nature of the purification process,
are also expected to be hydrophobic, the LCST cycling step should only be attempted at the
end of a given protocol. This is especially true for Ic and Id, for which coacervation was
observed to be irreversible in water.
Based on multiple fermentations, recombinant protein yields were in the range of
150-180 mg per liter for lb and Ic, while 100 mg of Id were obtained per liter for one
12-L fermentation run. Purification flow-charts and accompanying purification gels are
presented in Figures 2.4-6, below, and details are provided in the Methods section, above.
First efforts to encode lysine at the amino-terminus were intended to be minimally
invasive, to not diminish the already favorable expression levels observed by Panitch (i.e.
40 mg/L), and, thus, involved the short NK linker, given above as encoding MAKAM.
DNA sequencing was used to confirm both the directionality and sequence of the inserted
NK oligonucleotide in the unique Ncol site of the gene encoding la. The same procedure
was followed to ensure the integrity of the CK linker in the Xhol site of the same gene.
However, upon expression, no induced band was observed via SDS-PAGE at or neai" the
expected molecular weight of 59 kDa (data not shown). Radiolabeling confirmed the
induction and accumulation of target protein, and, therefore, various IL fermentations
29
were carried out. After applying the purification protocols developed for la, a final yield
of 4 mg/L was obtained. Thus, under the same expression and purification conditions,
there was an observed 10-fold decrease in protein yield, due to the insertion of the NK and
CK linkers alone.
Insertion of the T7K linker increased target protein yield. To optimize purification
protocols, the T7K linker was designed to encode one lysine residue and the T7-tag®
epitope (Novagen) that could be used as an antigenic handle to follow target protein
partitioning into given fractions. Expression lead to high induction and accumulation levels
of target protein, as observed in lanes 4 and 5 of Figure 2.3 (gel a). Purification protocols
were optimized with the use of the T7-tag fusion and Western blotting, and resulted in a
greater than 30-fold increase in yield over constructs with the NK fusion and a greater than
3-fold increase in yields reported for la. At this point, it is not known whether the
observed effects of upstream linkers on protein yield are sequence- or length-specific.
What can be concluded is that the CK linker does not deleteriously affect target protein
yield.
The expressed and purified proteins are indeed the engineered proteins Ib-d. This
statement is confirmed by several observations: first, at the genetic level, both the DNA
sequence and reading frame of the oligonucleotides, from which the artificial genes were
constructed, were confirmed as part of the cloning procedures; second, induction lead to
the expression of proteins near the expected molecular weight values, which are based on
the theoretical length and amino acid sequence encoded by a particular genetic construct;
third, as confirmed by Western analysis (data not shown) induced proteins carried the T7-
epitope tag, which was encoded by linker T7K; fourth, the solubility characteristics were
consistent with behavior expected of macromolecules that exhibit an LCST; and fifth,
measured amino acid compositions are commensurate with theoretical values, Table 2.1.
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Figure 2.4 Purification How chart (a) for proteins lb and Ic with accompanying 12%
SDS-PAGE gels of purification fractions, gels b and c, respectively.
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Figure 2.5 Purification flow chart for proteins Id with accompanying 12% SDS-PAGE
gels of purification fractions.
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Figure 2.6 12% SDS-PAGE of final purification products for proteins lb (top arrow) Ic
(middle arrow), and Id (bottom arrow).
Table 2. 1 Amino acid compositions of engineered elastin analogs.
/ b / c 1 d
Residue Then. n% Meas. n% Theo. n% Meas. n% Theo. n% Meas. n%
Asx 2.3 2.4 2.3 2.4 2.0 2.1
Glx 3.7 3.9 4.0 3.7 5.3 4.6
Ser 0.2 0.3 0.7 0.7
Gly 33.7 33.8 33.3 33.5 31.3 32.7
His 1.5 1.2 1.5 1.3 1.3 1.1
Arg 0.9 0.9 1.0 1.2 1.3 1.2
Thr 0.3 0.5 0.5 0.7 1.3 1.2
Ala 0.5 0.9 0.8 1.1 2.0 1.9
Pro 17.7 17.8 17.3 18.2 15.3 16.2
Tyr 1.5 1.3 1.5 1.4 1.3 1.1
Val 16.9 17.0 16.5 17.8 14.7 15.3
Met 0.8 0.8 1.3 0.9 3.3 2.5
ne 17.7 17.1 17.3 15.2 15.3 15.2
Leu 1.9 1.5 2.0 1.8 2.7 2.4
Phe 0.1
Lys 0.5 0.7 0.8 0.9 2.0 1.7
%VPGI 86.0 85.7 84.4 84.7 76.6 79.4
2.3.3 NMR Spectroscopy
Further characterization of the purified lb by NMR spectroscopy reveals major
resonances from the repeating elastin-like sequence Val'-Pro^-Gly'-Ile''-Gly^ (Figures 2.7-
2.9), an observation consistent with the fact these residues constitute 86% of the total
amino acid composition (Table 2.1).
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Figure 2.7 'H-NMR spectrum (600 MHz) of lb in formic acid.
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Figure 2.8 Complete *^C-NMR spectrum (500 MHz) of lb in formic acid.
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Figure 2.9 Regional '^C-NMR spectrum (500 MHz) of lb in formic acid.
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The assignment of both major and minor resonances was achieved with a
combination of spectroscopic methods and reported chemical shift values29. Major proton
resonances from valine, proline, and glycine residues were assigned above (Figure 2.7)
and in agreement with those reported by McPherson et aPO. Isoleucine peaks and minor
resonances were assigned using correlation spectroscopy (COSY) and total correlation
spectroscopy (TOCSY). The latter of these two-dimensional techniques was found to be a
powerful method in distinguishing spectral peaks, as each amino acid has a characteristic
resonance pattern and associated chemical shift values29. Once the 'H-NMR spectrum was
fully assigned and confirmed by TOCSY and COSY methods, the ''C-NMR spectrum was
fully assigned with the aid of literature spectral8,3l and heteronuclear single quantum
coherence spectroscopy (HSQC), where diagonal peaks correspond to correlations between
protons and the carbons to which they are bonded (Figure 2.10).
Ile8CH3
ValYCH3
ValyCH^
IleyCHj
He YCH2
Pro YCH2
PropCH2
GIUYCH2
Val p CH
He p CH
ppm 2.5
"1—
2.0
—I r
: 5 1,0
Figure 2. 10 HSQC-NMR spectrum of lb in formic acid, where lines are added for clarity,
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2.3.4 LCST
The lower critical solution temperature (LCST) represents a value below which the
elastin-like proteins are soluble in aqueous media and above which a protein-rich phase or
coacervate forms. This transition is manifested by a change in optical properties, where the
clear solution becomes opaque or turbid, upon raising the temperature above the LCST.
Panitch confirmed that this transition temperature was sub-ambient for la (12°C)l l, and
consistent with the value of 10±5°C predicted by Urry and coworkers for poly(VPGIG)32.
Since this transition is both a function of concentration and thermal scan rate, the LCST of
lb was measured at concentrations varying from 5-40 mg/ml and scan rates of 6, 12, 24,
30, and 48°C/hour. Consistent with Urry and Panitch, the concentration dependence of the
transition, at a fixed scan rate of 30°C/houri9, was limited to values less than about 20
mg/ml, at and above which the LCST was measured to be 16.7°C (Figure 2. 1 1). At a fixed
concentration, the LCST was observed to decrease with decreasing scan rate (Figure 2.12),
where at the lowest scan rate the LCST was determined to be 16.4°C. The effect of both
scan rate and concentration are summarized graphically in Figure 2.13.
The observed 4-5°C increase of the LCST of lb, relative to la, may be explained
by the addition of the hydrophilic, terminal fusions T7K and CK. This claim is supported
by the hydrophobicity scale developed by Urry et al., where, using a series of elastin-like
polymers having the repeating sequence of VPGXG, the LCST was observed to increase
or decrease with the substitution for X with hydrophilic or hydrophobic residues,
respectively32,33
Measurement of LCSTs for Ic and Id was complicated by the fact that
concentrated aqueous solutions (20-40 mg/ml) were slightly turbid below the LCST and the
transition was not reversible in aqueous medium. Even at moderate concentrations (2-4
mg/ml), aggregates that formed above the LCST were no longer soluble below the LCST,
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unless denaturants were used. This was not the case for lb, for which the transition was
reversible at all attempted concentrations, as assessed by optical turbidity. Urry observed
that this transition was fully reversible for poly(VPGVG), but not for poly(APGVG), and
that there was an inverse relationship between molecular weight and LCST12, 19,34, Xaken
together, these observations indicate that, although the transition may take place at a higher
temperature and concentration, the conformational changes associated with the transition
are more facile and stable for the shorter constructs.
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Figure 2. 1 1 LCST determination of lb as a function of concentration at a constant thermal
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Figure 2.13 LCST of lb as a function of scan rate and concentration.
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2.3.5 Solubility and e-Amine Titration
Although the e-amino moiety of the added lysine residues may be cross-linked with
a variety of electrophilic agents, glutaraldehyde (GTA) was chosen for initial cross-linking
studies, to evaluate the feasibility of such an endeavor. Glutaraldehyde has a long history
as a crosslinking agent for biomaterials35-37, and has been shown to react primarily with
the £-amino groups of lysine38 to give a mixture of products that are best described as
heterogeneous and complicated26,39,40
In the studies at hand, glutaraldehyde was used in solution or vapor phases^l. For
all studies, electron microscopy-grade, commercially-available, aqueous solution was used
(50 wt.%). Ultraviolet measurements of the purchased GTA revealed only one absorption
peak at 280 nm, indicating the lack of aldol condensation products that have an absorbance
at 235 nm26. Before exposing to GTA solutions in phosphate buffered saline, pH 7.4
(PBS), it was necessary to anneal the transparent films, which were cast below the LCST
from aqueous solutions, in a high humidity environment (ca 98%) for several hours, after
which they became hydrated and opaque. Otherwise, it was observed that the optically
clear films readily dissolved in the GTA solutions, even above the LCST. Using
radiolabeled protein lb, solubilization was monitored during 5 consecutive 24-hour
washes of PBS, pH 7.4, after a 2-hour exposure to 1, 10, or 100 mM GTA solutions and
neutralization with Dimedone (Figure 2.14). Insolubilization was determined to be at 94,
97, and 98% for GTA concentrations of 1, 10, and 100 mM, respectively.
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Figure 2. 14 Solubility of films of lb cross-linked with X mM GTA solutions, as a
function of wash time (error bars = S.D.).
GTA, having a boiling point of 100.12°C, has a sufficiently high vapor pressure,
like that of water, to be readily vaporized at ambient temperatures. Consequently, vapor-
phase crosslinking was carried out on cold-cast, transparent films of lb that were placed in
a closed environment containing a freshly prepared GTA solution. At exposure intervals of
3, 6, and 9 hours, films became progressively more opaque and tanned. As with solution
cross-linked films, solubilization was assessed with radiolabeled protein and consecutive
PBS washes (Figure 2.15), where control samples were exposed to a humidified
environment for 9 hours. Insolubilization was determined to be at 82, 92, 96% for
exposure times of 3, 6, and 9 hours, respectively. Thus, not only are both crosslinking
methods successful in insolubilizing lb, relative to la, where ca 75% was solubihzed in
three hours l"*, but similar levels of insolubilization can be achieved by either strategy. The
role of the added e-amino groups of the lysine residues in the crosslinking chemistry is
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implicated by the observation that films of la treated with either 100 mM GTA or exposed
to GTA vapor for 9 hours were readily solubilized in PBS, pH 7.4.
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Figure 2. 15 Solubility of films of lb cross-linked for X hours exposure to GTA vapor, as
a function of wash time (error bars = S.D.).
Cross-link efficiency, although implied in the above insolubilization assays, was
assessed via e-amine titration with 2,4,6-trinitrobenzene sulfonic acid (TNBS). Although
the exact nature of the crosslinked structure, especially with respect to the GTA domains,
may be impossible to elucidate, well-defined methods have been developed to quantify
unreacted amino groups of lysine side-chains2-'''26,42 Hydrolyzable Schiff base products
from the condensation reaction of GTA with primary amines are reduced with NaBH^, a
precautionary step to preserve the e-amine concentration, but, according to Old Damink and
coworkers, this is probably unnecessary, as all such bases present react with and are
stabilized by GTA under these experimental conditions'^. In fact, this same group has
shown that, under similar experimental conditions (PBS, pH 7.4, 55 mM GTA), on
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average, three GTA molecules are associated with each reacted amine, thereby supporting
the mixture of GTA reaction products. After this questionable reduction step, accessible e-
amines are reacted with TNBS (I) and the crosslinked structure (II) is hydrolyzed with
concentrated acid (Figure 2.16). Unreacted TNBS and a-amino trinitrophenyl amino acids
are extracted with diethyl ether and the optical peak absorbance is measured in the range of
3(X)-400 nm. The e-amine group content is calculated with the molar absorbtivity for
trinitrophenylysine (III) (14,600 M '-cm '). Based on all controls and standard solutions
used in experiments outlined below and in Chapter 4, it was determined that 86 ± 20%
(S.D.) of all free amines were accessible to this assay.
Protein— NHj +
DHCl, A
NOj NiiHCOj o^N^ NO2 2) Ether extraction
III
Figure 2. 16 TNBS / protein reaction scheme used to determine e-amine content.
Films cast from Ic were used to assess the free e-amine content as a function of
exposure time to GTA vapor. Similar to vapor-phase cross-linking of lb above,
radiolabeled films were cast from aqueous solutions (100 |il, 100 mg/ml), and exposed to
GTA vapor for intervals of 6, 12, and 24 hours. After which, samples were incubated in
NaBH4 (1.2 mg/ml, PBS, pH 7.4) for 1 hour, prior to 3 consecutive 24-hour washes with
PBS. Films without radiolabeled protein were cross-linked and reduced in parallel with the
radiolabeled films . These latter films were used for free-amine group determination.
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where any protein solubilized during the reduction step was accounted for by the
solubilization assays of the former films. These results are combined in Figure 2. 17,
where it is observed that the free e-amine content decreases by approximately 70% of the
control value (i.e. fixation index = 70%), regardless of exposure time. That is, under the
applied conditions, approximately three out of every four e-amines is accessible to GTA.
For these same conditions, progressively greater insolubility is achieved with longer
exposure times to GTA vapor. Interestingly, relative to the control, GTA increases the 73-
hour solubility of Ic for 6- and 12-hour exposure times, with greater insolubility observed
for the 24-hour cross-linking time alone. Taken together, these data indicate that accessible
amines react readily with GTA and significant crosslinking is achieved only at longer times.
It is unknown, whether these longer times are consistent with achieving adsorption
equilibrium of GTA/HjO, diffusion of GTA throughout the film, or reaction of GTA with
other amino acid side-chains, such as those of histidine, arginine or tyrosine27.43
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Figure 2. 17 e-Amine content, relative to controls, and 73-hour solubility of Ic exposed to
GTA vapor, as a function of exposure time (error bars = S.D.).
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Examination of the dispai ily in GTA vapor-phasc insolubilization of Ic, relative to
lb indicates that film thickness plays a major role in crosslinking efficiency. After a 6-
hour exposure to GTA vapor, the 1 mg film of lb was 92% insoluble (120 hr. wash),
while the 10 mg film of Ic was only 69% insoluble (73 hr. wash). These insolubilities are
directly comparable, regardless of the difference in solubilization wash times, since, in both
cases, greater than 95% of all soluble material was liberated in the first 48 hours of
wa.shing. Assuming equal reaction conditions, this disparity in insolubility most likely
arises from the difference in film thickness, which, based on the casting area, was three
times greater for Ic than for lb. Thus, accessibility of amines is apparently limited by the
diffusion of free GTA molecules throughout the thickness of the film, a process that is
most likely hindered by the multifarious reactions of GTA with itself and free amines neai-
the surface. As supported by the .solubility data of Figure 2.17, such a situation would
result in a cross-link density gradient with greater efficiencies observed near the free
surface and concomitant gradients in swelling'*'* and diffusivity.
A 10% higher fixation index was obtained with GTA solution crosslinking, as
compared to vapor crosslinking, under the applied conditions. After a 1-hour exposure to
various concentrations of GTA in PBS, pH 7.4, the free-amine content decreased with
increasing GTA concentration by as much as 79% of control values (i.e. fixation index =
79%) (Figure 2. 18). That the free-amine content decreases with increasing GTA
concentration seems to support the cross-link gradient and surface diffusivity barriers
implied by vapor-phase crosslinking. Crosslink density gradients may indeed exist in both
cases, yet, in the case of solution crosslinking, the initially hydrated, swollen films seem to
allow greater access to free-amines.
The combined GTA crosslinking results provide some insight into the network
structure. Depending on the phase of application and film thickness, GTA insolubilizes 69-
98% of the engineered proteins by reacting with 70-79% (Ic) of available free-amines,
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and, most likely, with non-uniform crosslink density, especially in the vapor-phase. The
exact stoichiometry and nature of the GTA crosslinks is unknown.
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Figure 2. 18 e-Amine content, relative to controls, after a I -hour exposure to GTA
solutions of various concentrations (error bars = S.D.).
2.3.6 Tensile Parameters
Tensile specimens were prepared by crosslinking with GTA vapor and solution,
successively. Vapor-phase crosslinking alone resulted in swollen, tanned films with a
smooth, lack-free upper surface and a sticky, often incoherent bottom surface, an
observation consistent with the crosslink gradient proposed above. Consequently,
vacuum-dried, optically clear films were first exposed to GTA vapor (12-18 hours) and
then to 10 mM GTA solution. Further crosslinking was inhibited by Dimedonc. Said
process resulted in swollen, tanned films of thickness varying from 0.09 - 0.375 mm,
depending on the initial quantity of protein cast. Strips of uniform width, varying from 9-
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12 mm, were cut from the films with a scalpel and straight edge. Paramount to the
determination of ultimate tensile parameters, such as strength and elongation, is the
exclusion of nicks in this cutting operation.
Tensile tests were performed under in vitro physiological conditions in a specially
designed test chamber (Figure 2.19). Modeled after similar chambers used to test
biological samples23,45^ samples are mounted, equilibrated, and tested in PBS, pH 7.4,
held at constant temperature (37°C) with circulating water in the outer vessel of the double-
walled test container. Based on ASTM standard D 882-91 "Standard Test Methods for
Tensile Properties of Thin Plastic Sheeting," a suitable standard for evaluating tensile
modulus of ela.sticity for polymeric films less than 1 mm in thickness, a uniform strain rate
of 10% of the gauge length per minute was used for all samples. Not consistent with this
standard, which suggests a minimal initial grip separation of 50 mm for materials having a
total elongation at break of 100% or greater, but not without precedence45-47, gauge
lengths of 12-25.4 mm were used, depending on the quality of the sample.
Based on minimum of five samples of each protein that were crosslinked under
identical conditions, representative stress-strain curves were generated (Figure 2.20).
Specifically, curves having parameters closest to the average, for a given protein, were
chosen as representative for that set. Since the elastic modulus of elastomers is a function
of strain'^^'49, the incremental moduli better characterize the elastic material response, and
are therefore presented as a function of strain in Figure 2.2 1
.
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Figure 2. 19 Schematic of physiological test fixture, where sample D mounted in grips that
are adjustable by threaded rods C, all of which are submersed inside the double-walled,
glass vessel B supported by platform jack C that rests on frame A, which is firmly bolted
to testing machine (scale 1" = 2").
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Figure 2.20 Representative stress-strain curves for crosslinked, engineered proteins Ib-d.
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Figure 2.2 1 Representative incremental moduli as a function of strain
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les a
statistical treatment of idealized networks from rubber elasticity theory provid,
relationship between stress (a) and strain (elongation ratio X) and shear modulus (G),
namely g = G(X- l/X\ which agrees well with experimental curves for strains below 50%
(X below 1 .5)50. Thus, for an elastomeric system, as these are assumed to be, a plot of a
versus (X
-
l/X') should be linear, having a slope equal to G. For crosslinked networks of
proteins Ib-d this indeed holds true (Figure 2.22). Furthermore, for ideal networks, G is
inversely proportional to the molecular weight between crosslinks through the
relationship
G
where the numerator is the product of the polymer density, ideal gas constant, and
temperature, respectively. Consequendy, since proteins are monodisperse having crosslink
points at the ends of the chains, G should be related to the reciprocal molecular weight in a
linear fashion and be equal to one-third Young's modulus, as is the case in Figure 2.23.
Using the measured shear moduli, the molecular weight between crosshnks can be
calculated. Assuming an ideal network (Equation 1) and a protein density of 1.3 g/cm^ a
value equivalent to that of collagen23, values of 78.1, 48.1, and 27.5 kDa were
calculated for la, Ic, and Id, respectively. These values are 1.3 to 2 times greater than
the protein masses, indicating inefficient crosslinking. That is, a network in which all
putative crosslink sites (amines) were either not consumed or participated in reactions that
did not lead to crosslinks, such as tethering or intramolecular loop formation. While this
suggestion is supported by the e-amine titration data, non-monomeric GTA (i.e. oligo- and
polymeric GTA) crosslinks may also contribute to the higher values, a hypothesis
difficult to prove^^.
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Average tensile parameters of crosslinked Ib-d are given in Table 2.2. The
measured instantaneous Young's moduli E(0) are well within the range of 0.001 - 10 MPa,
reported by Urry et al. for elastin-like polymers crosslinked via y-irradiationS 1
,
and, at the
highest crosslink density (Id), approximate the elastic modulus of native elastin: 0.3 -
0.652 MPa. Based on a molecular weight of 68,419 Da and 14 cross-link sites53, fully
crosslinked human elastin would have an approximate of 5,000 Da. Assuming that this
crosslink density is achieved, an assumption more likely with increasing age54, values
between the lower, theoretical value of 5,000 and that of 14,000 for Id, indicate a range in
which moduli may be varied to equal that of native elastin. That genetic engineering
provides a method for prescribing indicates that precise control within this range may be
achieved. Due to the susceptibility of ultimate parameters, such as strength ct^- and
elongation E^, to mishandling, voids, nicks, and improper gripping, no clear relationships
between these parameters and M or are indicated by the data. With this caveat in mind,
the elongation at break for Id is in agreement with the upper end of the range reported by
Abbott and Cambria, specifically 100 - 220%.
Table 2.2 Average tensile parameters.
Parameter Elastin" Id (n=5) Ic (n=9) lb (n=9)
M (kDa) 14.0 36.6 59.2
E(0) (Mpa) 0.3 - 0.6 0.321 ± 0.057 0.195 ± 0.037 0.0994 ± 0.026
G (MPa) 0.122 ± 0.02 0.0697 ± 0.008 0.0429 ± 0.0086
ax (MPa) 0.4 - 4.4 0.527 ± 0.29 0.873 ± 0.19 0.346 ± 0.058
EJ%) 100-220 251 ± 52 393 ± 13 389 ± 14
Fitting Equation
(Representative
Curves)
N/A
y=0.091+0. 285x-
0.101x'+0.0252x'
(r=0.9997)
y=-0.006 1+0.21 8x-
0.0940x'+0.0249x^
(r=0.9995)
y=0. 0594+0. 893x-
0. 0253x^+0. 00732x'
(r=0.9998)
Although the measured moduli are inversely related to the molecular weights of Ib-
d, as predicted by ideal network theory, these are clearly not ideal networks. The ideal
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network is isotropic and composed of freely-joined chains that obey Gaussian statistics and
that do not interact with each other (i.e. the internal energy of the system is independent of
chain conformation)48. While some polymeric networks are more ideal than others^O,
proteins exhibit specific inter- and intra-chain associations that lead to well-known
structures, such as a-helices, P-sheets, etc., and, therefore, are not ideal. For these elastin
analogs, specific interactions are implicated by aggregate formation (fibrillogenesis), optical
turbidity, conformational changes, and a variety of other observed indications34.
Urry has elucidated that protein elasticity, for crosslinked elastin analogs, does not
require a random chain network, but rather is derived from internal chain dynamics via a
"librational entropy mechanism of elasticity34." Specifically, the nonrandom p-spiral, a
helical structure that forms to optimize intramolecular, hydrophobic side-chain interactions,
exhibits large-amplitude, low-frequency rocking motions for which vibrational entropy
decreases upon stretching. Furthermore, Urry suggests that the characterization of protein
systems, in terms of random chain networks, is unnecessary and possibly incorrect, as
indicated by a dramatic loss of elastic modulus, upon thermal denaturation. This drop in
modulus, while implicating the p-spiral as the predominant source of entropic elasticity,
does not, however, deny the applicability of explicit network theories to conditions where
the protein interactions are minimized via denaturation, conditions that more closely
approximate an ideal Gaussian network. To the contrary, under appropriate conditions,
denatured collagen, which forms characteristic higer order structures, has been shown to
behave like an ideal rubber^^, and network parameters, such as M^, can be calculated from
state equations for ideal rubber elasticity48 and/or swelling equilibrium^^. In fact, Yannas
and coworkers have applied these principles to the development of artificial skin that is
based on well-defined networks of collagen23.56
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What appears to be certain is that there are conditions under which an array of
protein interactions dominate and dictate network response to an appHed force, yet, the
inverse relationship between and elastic modulus still applies. That is, even when ideal
conditions are not invoked by denaturation, elastomeric force per unit area (modulus) varies
inversely with M,. In support of this claim are the measured moduli of crosslinked Ib-d,
the ranges of moduli and crosslink densities of Yannas and coworkers23,56^ ^nd even the
range of moduli reported by Urry et al. that vary as a function of crosslinking^
' . Thus,
Urry's suggestion that Gaussian network theory is not applicable to protein networks
should be clarified by stating that empirically, the relationships between modulus,
temperature, and hold true, while explicit relationships predicted by rubber elasticity
theory, which ignore the increase in internal energy derived from intra- and intermolecular
interactions, apply only under denaturing conditions, where such interactions are
minimized.
2.4 Conclusions / Future Work
Methods of genetic engineering were successfully applied to the design and
biosynthesis of three extracellular matrix protein analogs having the same primary sequence
but different molecular weights. Expression levels were enhanced by the serendipitous
choice of an N-terminal fusion sequence such that gram-scale syntheses were achieved for
each protein. Purification protocols were developed that resulted in proteins of high purity
and of the correct sequence, as determined by amino acid analysis, NMR spectroscopy,
and existence of an LCST, which was measured to be 4-5°C higher than the base protein
from which these analogs were derived.
The success of the design strategy, in providing a means of control over physical
and mechanical, was demonstrated. Glutaraldehyde was shown to insolubilize the
otherwise soluble proteins in a concentration-dependent manner with a fixation index of
70% in the vapor-phase and 79% in the solution phase, as determined by free-amine
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content. In spite of apparent crosslink density anisotropy, tensile moduli were measured
and found to be inversely related to the molecular weight of the engineered proteins, the
theoretical molecular weight between crosslinks. Furthermore, at the highest crosslink
density (lowest molecular weight) the elastic modulus was in agreement with that of native
elastin.
These results indicate that this strategy may be extended to achieve precise control
of macroscopic material properties through judicious manipulations at the genetic level.
Such control has enormous implications in improving vascular graft patency, where
matching the elasticity of artificial grafting materials to that of native vessels is
paramount52.
Although implicit to these preliminary insights into structure/function relationships
of systems of this kind, strategies for future engineering endeavors should include
provisions for the detailed analysis of the network structure and alternate crosslink
strategies. Glutaraldehyde, while effective, leads to an ill-defmed network structure, both
with respect to chemical structure and crosslink density. To gain ultimate control over and
understanding of these systems, a well-defined and well-behaved crosslinking agent is
prescribed. Evaluation of such an agent will undoubtedly and necessarily be in terms of
network parameters.
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CHAPTER 3
AMINE-CONTAINING ELASTIN ANALOGS: BIOLOGICAL PROPERTIES
3.1 Introduction
Owing to the lack of materials suited for small-diameter vascular grafts, efforts have
been focused on the design and synthesis of polymers having well-controlled biological
and physical properties. Ideally, such a material would promote or sustain
endothelialization, a biological property paramount to the patency of vascular prostheses,
and would have well-defined elastic characteristics, as those described in the preceding
chapter. With this end in mind, blocky copolypeptides have been designed in which one
block consists of an endothelial cell-binding domain derived from fibronectin and the other
block is an elastin analog ^ '2.
The cell-binding block is derived from the altematively spliced type III connecting
segment (IIICS) of fibronectin known as the CSS domain. Humphries et al. have shown
that the minimal peptide sequence recognized by endothelial cells is the tetrapeptide Arg-
Glu-Asp-Val (REDV)3.4^ ^nd have elucidated that recognition and adhesion is through the
a^^^ integrin, a cell-surface receptor^. Hubbell and coworkers have confirmed the
endothelial cell specificity of this peptide, relative to other cell types, and have also reported
minimal surface densities of the binding ligand for endothelial cell adhesion, as well as
ligand binding sites per cell^'^.
In contrast to the results reported by Nicol et al.^, where the minimal adhesion
peptide REDV was copolymerized with VPGVG, at various concentrations, Panitch et al.
observed endothelial cell adhesion and spreading on CS5-containing elastin analogs^.
Specifically, endothelial cell adhesion was shown to be dependent on the CS5-ligand
density, where the engineered polypeptide with the higher CSS content, at approximately
the same frequency as those used by Nicol et al. (i.e. VPGVG:REDV, 20:1), supported
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greater cell attachment and at levels similar to the fibronectin control. These contradictory
results may be explained by the anticipated differences in conformation and consequent
interaction of flanking residues of the longer CS5 region with the adhesion receptor, an
interaction further affected by the differences in background, elastin-like blocks and in the
chemistry of crosslinking. However, the most likely explanation lies in the cell harvesting
method, where Panitch et al. used non-enzymatic means and Nicol et al. employed trypsin,
an enzymatic treatment known to cleave the extracellular domain of the subunit of the
adhesion receptor^, thereby rendering the putative binding mechanism inoperable.
While CS5-containing analogs derived from the work of Panitch have been
modified in a precise way to achieve well-defmed mechanical properties (Chapter 2), the
effect of glutaraldehyde (GTA) crosslinking on cellular adhesion was unknown. A
negative control protein was synthesized without the CS5 domain having the same elastin-
like sequence (VPGIG)„ and with lysine residues encoded at the termini to achieve amine-
specific crosslinking, as with the CS5-containing analog, Figure 3.1. Thus, cellular
activity may be evaluated on substrates crosslinked by the same chemical means with and
without the adhesive ligand.
MMASMTGGQQMGRKTMG[LDCS5G(VPGIG)2oVP]^LEKAAKLE (CS5-EL)
MMASMTGGQQMGRKTMG-(VPGIG)4oVP-LDGVPGKGVPGIGVPGKG (EL)
Figure 3.1 Primary amino acid sequences of CS5-containing (CS5-EL) and CS5-free
(EL) elastin analogs, where CS5 = GEEIQIGHIPREDVDYHLYP.
The following discussion will focus on the synthesis of the control protein EL,
substrate preparation, and cellular interactions with the same. Specifically, the ability of
crosslinked films of CS5-EL and EL to support attachment and spreading of two cell
types will be evaluated: namely, human umbilical endothelial cells (HUVECs) and human
umbilical artery smooth muscle cells (UASMCs).
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was
3.2 Experimental Section: Materials and Methods
3.2.1 General Methods
Standard molecular biological techniques were used for DNA manipulations,
bacterial growth, electrophoresis, and Western blotting, as prescribed by well-defined
protocols'". Restriction and modifying enzymes used in genetic manipulations
obtained from New England Biolabs (NEB), Beverly, MA. DNA sequencing
performed by the DNA Sequencing Facility at the University of Massachusetts Amherst.
Large scale fermentations were achieved with New Brunswick Model MF-214 (10-12 L)
fermentors. A Bruker AMX 500 MHz spectrometer was used to obtain '^C- and 'H-NMR
spectra. Amino acid analysis was performed at the New York State Center for Advanced
Technology at Cornell University. MALDI-TOF mass spectrometry was run at the Mass
Spectrometry Center at the University of Massachusetts Amherst with a Bruker ReflexTMIII
mass spectrometer in linear mode. Tissue culture substrates and cells were visualized and
photographed with a Nikon Optiphot phase-inversion microscope equipped with a Nikon
35mm camera.
3.2.2 Design and Cloning of Control Protein
The expression vector carrying the gene of interest (pET28ap) was previously
modified by deletion of the polycloning site between the Ncol and Xhol restriction sites of
pET28a (Novagen, Milwaukee, WI) and insertion of an 20-base pair linker into which the
gene encoding (VPGIG)4o ligated'. Said vector was entitled pET28ap(VPGIG)55, a
discrepancy in VPGIG repeat number to be discussed below. Lysine encoding linkers
T7K (Chapter 2) and Lys2 (Figure 3.2) were ligated into the Ncol site at the 5'-end of the
gene, and the Xhol site at the 3 '-end of the gene, respectively.
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Xhol I Sail
] XhDl
Tr^f ^ '''''' ''''^ AAA GGT TAA C
^
G CCA CAA GGC CCG TTT CCA CAT GGC CCG TAG CCA CAA GGC CCG TTT CCA A^GAG CT
Asp Gly Val Pro Gly Lys Gly Val Pro Gly He Gly Val Pro Gly Lys Gly OCH
Figure 3.2 Lysine-encoding oligonucleotide of CS5-free elastin analog.
Oligonucleotides were obtained from Genosys (The Woodlands, TX). Crude
oligos were resuspended in 10 mM TE buffer (10 mM Tris-HCl, 1.0 mM EDTA, pH 8.0)
at a concentration of 0. 1 mM. A 100 |il annealing solution (100 mM NaCl, 20 mM MgCl^)
containing 6 |xg of each of the complementary oligos was heated to near boiling and
allowed to cool slowly to room temperature. Annealed oligos were ethanol precipitated
(0.1 volumes 3.0 M NaOAc, pH 5.2, 2 volumes 100% ethanol, 15 minute incubation at -
80°C, 30 minute centrifugation, 2 volumes 70% ethanol wash via 5 minute centrifugation),
dried and resuspended in a 50 |il phosphorylation reaction volume, which consisted of 1 x
T4 ligase buffer (NEB) and 0.5 |li1 T4 polynucleotide kinase (NEB). The reaction was
allowed to proceed at 37°C for 1 hour, after which a phenol:chloroform (1:1) extraction
was performed to remove the kinase. Oligos were concentrated via ethanol precipitation,
resuspended in 10 mM Tris, pH 8.0, and quantified with standard DNA markers via
polyacrylamide gel electrophoresis (PAGE) in TBE buffer (0.089 M Tris-borate, pH 8.3, 2
mM EDTA).
Vector pET28ap(VPGIG)55 was cloned from glycerol frozen stock #47 of AP
(Alyssa Panitch) Box 101 and was isolated by commercially available chromatographic
methods (QIAprep®, Qiagen, Valencia, CA) or by an alternate alkaline lysis method, as
described in Chapter 2. Isolated vector was then linearized with the appropriate restriction
enzyme and dephosphorylated with calf intestinal phosphatase, according to the suppliers
recommendations (NEB). Linearized vector was isolated and quantified via agarose gel
electrophoresis in TBE and excision of the appropriate band from the gel, from which the
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DNA was purified with a kit from Qiagen (QIAex n®). Ligation of insert into vector was
most readily achieved by adding a given amount of Hnearized vector to a 15 ^tl reaction
mixture of 1 x T4 ligase buffer, heating to 65°C for 5 minutes, followed by a 5 minute
incubation on ice, and addition of a corresponding quantity of insert and T4 DNA ligase.
The reaction was then allowed to warm to room temperature slowly overnight.
Half of a given ligation mixture was used to transform E. coli strain DH5aF' or
BL21(DE3)pLysS (Novagen), for cloning or expression, respectively
. Transformed
colonies were screened for insert via the alkaline lysis mini-prep method, described above,
after growth in rich, 2xYT medium (16 g casein hydrolysate, 10 g yeast extract, 5 g NaCl
per liter) under antibiotic selection (34 |ig/ml kanamycin, SIGMA, St. Louis, MO).
Presence and fidelity of linker were confirmed via restriction mapping and DNA
sequencing. The expression strain was labeled as BL21(DE3)pLysS-pET28apT7K-
(VPGIG)4o-Lys2.
3.2.3 Fermentation and Protein Expression
Bacterial cultures were maintained under antibiotic selection in all stages of growth
and were grown from a single colony picked from a freshly streaked plate. Single colonies
were used to inoculate 5 ml Luria-Bertani (LB, 10 g casein hydrolysate, 10 g NaCl, 5 g
yeast extract, 1.0 ml 1 M NaOH per liter) and grown to near saturation (8-16 hours).
Subsequent LB cultures were started using a 100-fold dilution of inoculum volume, i.e. 5
mililiters of saturated culture was used to inoculate a 500 ml culture. Batch cultures of
volumes of 1 or 12 liters were allowed to grow at 37°C, under aerated conditions, to an
optical density range of 0.8-1.5, as determined by optical absorbance measured at 600 nm
(OD^oo). Target protein expression was induced by addition of 0. 1 M P-isopropyl
thigalactoside (IPTG, CalBiochem, La Jolla, CA) to a final concentration of 1.0 mM.
63
Expression was allowed to continue for 4-6 hours, during which time the optical density
reached a plateau in the range of 2.5 < 0D^< 3.5. Cells were harvested via centrifugation
(2,500g, 20 minutes, 4°C). Induction was confirmed by SDS-polyacrylamide gel
electrophoresis (PAGE) and Western blot analyses, where a T7-tag® antibody HRP-
conjugate (Novagen) was used in the Western blots.
3.2.4 Purification and Yield of T7K-(VPGIG)4o-Lys2
Harvested cell pellet was resuspended in 3 volumes of TEN buffer (10 mM Tris-
HCl, pH 8.0, 1 mM EDTA, 0.1 M NaCl], frozen, and thawed. To the thawed whole-cell
lysate, phenylmethylsulfonyl flouride (PMSF, SIGMA) (ImM), MgCl2 (5 mM), RNAse
(10 [Lg/ml), and DNAse (10 ^ig/ml) were added and allowed to incubate at 37° for several
hours. Target protein was partitioned to the pellet fraction via centrifugation at elevated
temperatures (20,100g, 60 min., 25°C) and was successively extracted from this pellet at
low temperature (4°C) with 5.0 M urea and sterile water. The resultant extracts were
dialyzed against cold, distilled water in the presence of an antimicrobial (Thimerosal,
SIGMA) to remove residual salts. Target protein was found in both the supernatant (S2A)
and pellet (P2A) fractions, upon centrifugation below the LCST (20,100g, 60 min., 2°C).
S2A was lyophilized and resuspended in buffer AAE at 4°C (0.05 M ammonium acetate,
5.0 M EDTA, pH 7.0). In a cold room (4°C), 1.5 volumes of n-propanoi and 2.5 volumes
of n-butanol were successively added in a dropwise fashion, while stirring. The resultant
solution was then filtered with Whatman fast-flow paper or centrifuged (10,000g, 20 min.,
4°C). The alcohol-soluble fraction (S3A) was dried 90-95% in vacuo at 40°C in a rotovap
or vacuum oven, and was then washed twice with 40 ml of chloroform to remove lipids.
The final product (A) was obtained after resuspending the viscous slurry in buffer UPT
(8.0 M urea, 0.1 M NaH2P04, 10 mM Tris, pH 7.0), dialysis against cold water, and
lyophilization. Target protein was pelleted from P2A after resuspension in 0.5% SDS,
followed by overnight incubation at 4°C and centrifugation (20,100g, 30 min., 20°C). The
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SDS-insoluble pellet (P3B) was resuspended in a minimal volume of pyridine, which was
then exchanged with AAE via dialysis (4L, 4°C, 24 h.), and subjected to the alcohol-
solubilization procedure described for S2A, resulting in product B. Final products A and B
were combined to give a yield, based on one 12 L-fermentation and coincident with the
elucidation of the above-outlined purification protocol, of 33 mg/L. Purity was assessed
qualitatively via SDS-PAGE, and quantitatively by amino acid analysis and NMR.
3.2.5 Substrate Preparation
Substrates for tissue culture were prepared as follows: Glass coverslips, 12 mm in
diameter, were used directly after cleaning in 100% ethanol or were amine functionalized
by a 5 minute exposure to 0.1% 3-aminopropyItriethoxy silane (Aldrich) in 95% ethanol,
rinsed with ethanol, and oven-cured for 1 hour at 100-1 10°C. Protein films were attained
by casting 40 ^il of aqueous protein solution (2.5 mg/ml) on aminated glass coverslips at
4°C and allowed to dry overnight. Subsequent films were crosslinked and covalently
attached to glass substrates via successive exposure to OTA vapor (12h, 25°C) and solution
(10 mM in PBS, 2h, 25°C). Films were rinsed extensively with PBS, residual aldehyde
was inactivated with dimedone (0.1-0.2 % in PBS, 24h, 25°C), and, after further rinsing,
were stored at 4°C in PBS. Human plasma fibronectin (hPFN, GibcoBRL, Gaithersburg,
MD) was cast from aqueous solution (40 \x\, 100 |ig/ml) onto non-functionalized glass
coverslips and allowed to dry under ambient conditions. Prior to cell seeding experiments,
all coverslips were washed with PBS, pH 7.4, exposed to UV radiation overnight, and
preincubated in serum-free culture medium for 2 hours.
3.2.6 Endothelial Cell Culture
Human umbilical vein endothelial cells (HUVECs, Clonetics, San Diego, CA) were
cultured in two types of endothelial cell growth medium: 1) EGM® (Clonetics)
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supplemented with human recombinant epidermal growth factor (10 ng/ml), hydrocortisone
(1 ^lg/ml), gentamicin (50 ^g/ml), amphotericin-B (50 ng/ml), bovine brain extract (12
^ig/ml) and fetal bovine serum (FBS, 2%); or 2) EGM®-2 (Clonetics) containing a
proprietary mixture of the above supplements, except bovine brain extract, and containing
vascular endothelial growth factor, human fibroblast growth factor-B, long insulin-like
growth factor- 1, heparin, and ascorbic acid. Cell cultures were maintained at 37°C in 5%
CO^ in a humidified incubator. Sub-culturing was performed when >80% confluence was
attained and by non-enzymatic means, for all passages. HUVECs were used before
passage 10, not including any prior subculturing steps by the supplier.
HUVECs were rinsed with warm PBS or Hank's balanced salt solution (HBSS)
(each without added Ca^^ or Mg^*) and were harvested non-enzymatically with 0.54 mM
EGTA (SIGMA) in PBS, pH 7.2-7.4 or with Versene (0.02% EDTA in PBS)
(GibcoBRL). Cells were concentrated via centrifugation (200 x g, 5 min.), resuspended in
a minimal volume of divalent cation-free PBS or HBSS, and counted with a
hemacytometer. Cells were then diluted with serum-free growth medium to a concentration
of 20,000 cells/ml, 1.0 ml of which was seeded into each well of a 24-well plate containing
the test substrates (fmal seeding density = 10,000 cells/cm^). After a given incubation time
(37°C, 5% CO2), culture medium was removed via aspiration, substrates were rinsed
gently with PBS or HBSS, and photographs were taken to assess morphology. Samples
were prepared, seeded, and counted in triplicate. An unpaired, two-tailed student's t-test
was used to evaluate variance and error was propagated using standard methodsl^.
3.2.7 Smooth Muscle Cell Culture
Umbilical artery smooth muscle cells (UASMCs, Clonetics) were cultured in
smooth muscle growth medium (SmGM®-2, Clonetics) supplemented with human
recombinant epidermal growth factor (0.5 ng/ml), insulin (5 |Ltg/ml), human fibroblast
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growth factor-B (2 ng/ml), gentamicin (50 |ig/ml), amphotericin-B (50 ng/ml), and fetal
bovine serum (5%). Cell cultures were maintained at 37°C in 5% CO, in a humidified
incubator. Sub-culturing was performed when >80% confluence was attained and by non-
enzymatic means, for all passages. UASMCs were used before passage 10, not including
any prior subculturing steps by the supplier, and were harvested, diluted, counted, seeded,
and assessed as described for HUVECs, above.
3.2.8 Cell Counting and Morphology Assessment
Adherent cells were counted using a cell proliferation assay kit, CyQUANT®
(Molecular Probes, Eugene, OR). After rinsing off non-attached cells, as described above,
coverslips coated with substrate and adherent cells were transferred to a new micro-well
plate and stored at -80°C. According to the suppliers recommendations, substrates were
warmed to room temperature and a proprietary lysis buffer (1 ml) containing a green
fluorescent dye, which interacts with cellular nucleic acids, was added. Since the number
of cells to be counted was expected to be at the lower end of the detection range for the kit,
the CyQUANT GR dye was dilute 800X with lysis buffer, in contrast to the recommended
400X by the supplier. Lysis and concomitant dye interaction were allowed to proceed for
30 minutes in the dark and under constant agitation. The buffer was then removed, diluted
with an equal volume of dye/lysis buffer ( 1 ml) in a cuvette, and the fluorescence was
measured with excitation at 480 nm and peak emission near 520 nm. For each sample,
three emission scans (510-560 nm) were averaged and 10 nm excitation and emission
slitwidths were used. Calibration curves were made for both cell lines as follows:
harvested cells were counted, concentrated via centrifugation (discarding supernatant),
frozen (-80°C), treated with dye/lysis buffer, and diluted serially (17,500 - 50 cells);
fluorescence intensity was measured, as above.
Morphology was determined from photographs taken immediately after removal of
non-adherent cells. Cells were either categorized as spread(ing), where nuclei and
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pseudopodia were distinguishable, or as non-spread(ing), which were categorized by the
lack of pseudopodia and by a rounded, refractile morphology. For each substrate, a
minimum of three fields or entire photographs were evaluated. The percent of control
spreading was determined by first calculating the number of spreading cells for a given
substrate (i.e. the product of fractional spreading from morphology assessment and total
number attached from counting assay), dividing by the number of spreading cells on
fibronectin, and multiplying by 100. Error in measurements was taken as the standard
deviation from average values and was propagated in subsequent calculations.
3.2.9 Competitive Inhibition Assays
HUVECs were harvested non-enzymatically, counted with a hemacytometer, and
resuspended in serum-free EGM® or EGM®-2 (Clonetics) containing 2 mg/ml heat-
denatured BSA (90°C, 10 min.) at a concentration of 1.2 X 10^ cells/ml. A given amount
of stock peptide solutions (10.0 mg/ml IxPBS, pH 7.4) were diluted in separate, sterile
tubes to 0.5 ml final volume with EGM® or EGM®-2 to achieve a given peptide
concentration. To these peptide solutions were added 0.5 ml (60,000 cells) of the
concentrated cell suspension, and the mixtures were allowed to incubate for up to 30
minutes, diluted with 2.0 ml growth medium with 1 mg/ml BSA, and seeded in triplicate at
10,000 cells/cm^. Cultures were maintained at 37°C and 5% COj for 4 hours, prior to
rinsing, photographing, and counting cells.
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3.3 Results and Discussion
3.3. 1 Cloning and Control Protein Expression
An existing genetic construct served as the starting point for the development of the
poly(VPGIG), negative control. Previous efforts of Panitch resulted in a construct labeled
pET28ap(VPGIG)55 that, when induced, revealed protein expression at the approximate
target molecular weight 24,493 Da, as detected by radiolabeling experiments!. Since
expression levels were low and undetectable via standard staining techniques, purification
methods were not elucidated. Consequently, no analytical or tissue culture data were
collected'
.
Since this represents an important CS5-free variant of the engineered elastin
analogs of the present studies, it seemed crucial as a negative control substrate for tissue
culture experiments.
The T7K linker was added to the 5'-end of the gene encoding poly(VPGIG). This
strategy had proven useful in optimizing purification protocols via the TV-tag epitope, an
antigenic marker easily probed and visualized in Western or dot blot analyses, and was
shown to possibly augment expression levels of CS5-containing analogs (Chapter 2).
Ligation of the 45-base pair T7K linker was confirmed by restriction analysis and DNA
sequencing (data not shown). Expression of this construct was confirmed by a faintly
stained band with SDS-PAGE, Western analysis, and amino acid analysis of the protein
purified at a yield of 15-20 mg/L (data not shown). Thus, the linker proved to be
extremely useful in isolating an otherwise abandoned construct.
A true control for the CS5-containing variants should ideally be crosslinkable via
the same general mechanism. That is, an amine functionality of four should exist; two at
each end of the protein. To achieve this at the C-terminus, a variety of linkers were
employed, all of which encoded a minimum of two lysine residues (Table 3. 1). The first
listed protein is that encoded by the existing genetic construct and all subsequent variations
include the amino-terminal T7K fusion. Multiple attempts to ligate CK linker into the 3'-
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end of the gene resulted in one copy inserted in the reverse orientation followed by
copy correctly oriented. However, this construct, for unknown reasons, failed to express
at levels comparable to those observed before the modification. Consequently, this
construct was abandoned and four alternate linkers, entitled Lysl-4, were pursued in
parallel. Since short linkers appear to affect protein expression, constructs containing
Lysl-4 were induced and those showing high levels of expression (Lys 2-4) were
submitted for DNA sequencing (Figure 3.3). Ambiguous sequencing results for the Lys 4
construct excluded it from further investigation. Attempts to purify Lys2 and Lys3
constructs in parallel, resulted in the isolation of Lys2 before Lys3, which vanished in a
multitude of purification fractions. Consequendy, the Lys2 construct was chosen for
subsequent studies.
Table 3. 1 Family of poly(VPGIG) proteins designed and expressed with varied success.
N-Terminal C-Terminal
Primary Sequence Fusion Fusion Yield
MG(VPGIG)4„VPLE none none no / low
MMASMTGGOQMGRKT- T7K none 15-20 mg/L
MG(VPGIG)4oVPLE
MMASMTGGQQMGRKT- T7K CX no / low
MG(VPGIG)^,VPLE-
FSSFLEKAAKLE
MMASMTGGQQMGRKT- T7K Lysl low /
MG(VPGIG)4„VPLD- unconfirmed
GVPGKGVPGKG
MMASMTGGQQMGRKT- T7K Lys2 33 mg/L
MG(VPGIG)„,VPLD-
GVPGKGVPGIGVPGKG
MMASMTGGQQMGRKT- T7K Lys3 unknown
MG(VPGIG)4oVPLD-
GVPGIGVPGIGKAAK
MMASMTGGQQMGRKT- T7K Lys4 unconfirmed
MG(VPGIG)4„VPLD-
GVPGKGVPGKGRGSHHHHHH
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Figure 3 3 Western blot of poly(VPGIG) constructs. T7-tag antibody: N-terminal T7K
fusion alone (lane 1, t = 0: lane 2 t = 4 hr.) and with C-terminal Lysl (lane 3, t = 0: lane 4 t
= 4 hr.), Lys 2 (lane 5, t = 4 hr.), Lys 3 (lane 6, t = 4 hr.), and Lys 4 (lane 7 t = 4 hr )His-tag antibody; Lys 4 (lane 8, t = 0; lane 9, t = 4 hr.).
Worthy of discussion is the disparity in molecular weights observed between the
LysX-containing constructs. Starting at the genetic level, digestion of the plasmid labeled
pET28ap-(VPGIG)55 with the restriction endonucleases Nco I and Xho I should have
generated a fragment 839 base pairs in length. However, said digestion generated a
fragment between 600 and 700 base pairs, a size consistent with 8 copies of the genetic
monomer, which encodes 5 tandem repeats of the sequence VPGIG, plus linker fragments
(calculated value = 614 bp, lane 3, Figure 3.4). Regardless of the disparity between the
frozen stock label and the actual gene size, Lys2-containing protein had decreased
electrophoretic mobility, compared to the other constructs, which ran at or near their
expected molecular weights, based on gene sequences and lengths (Figure 3.2). This
curious behavior of the Lys2 construct, which had a calculated mass of 20,512 Da, was
also evident in subsequent expression gels (such as Figure 3.5) and the mass of 24, 529 Da
measured by matrix assisted laser desorption mass spectrometry (MALDI), Figure 3.6.
Since all constructs were derived from the same gene and all expressed proteins, except
Lys2, ran at or near the expected molecular weights, it was concluded that the anomalies in
size and electrophoretic mobility were inherent to the Lys2 linker itself.
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i 2 3
Figure 3.4 1% Agarose gel of Nco \IXho\- digested DNA fragments from
pET28apT7K(VPGIGVLys 2 (lane 2) and pET28ap-(VPGIG)4o (lane 3), where lane 1
contams a standard having the indicated sizes in base-pairs.
1 2 3
Figure 3.5 12% SDS-PAGE gel of Lys2 construct (arrow) before (lane 2) and 4 hours
after induction (lane 3), where markers in lane 1 have the indicated molecular weights.
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3.3.2 Protein Purification and Yield
In spite of the detailed protocols developed for the CS5-containing elastin analogs
of the preceding chapter, supplemental steps were required to purify the poly(VPGIG)
control protein (EL). The target protein was found to partition in the pellet fraction of the
whole cell lysate and was thus treated as the longer CS5-containing proteins. However,
both the pellet and supernatant fractions P2A and S2A were enriched in protein and
contained a heterogeneous population of contaminants. Coacervate pellets, obtained by
warming S2A above the LCST and centrifugation, were cold-water insoluble and similarly
impure. EL was finally isolated by the scheme outlined in Figure 3.7, which represents ar
adaptation of protocols developed to purify mammaUan tropoelastin'2.13. Key to this
protocol was the selective solubility of EL in n-propanol and n-butanol (1:1.7,
respectively) and selective insolubility of SDS-EL aggregates'^.
Fhw Chart in Figure 2.4
S2A P2A
1) Resuspend in cold (4°C) buffer AAE(= volume)
2) In cold-room with all buffers cold add dropwise while stirring
1 .5 volumes of n-propanol, followed by
2,5 volumes of n-bulanol
3) Filler solution with fast-flow paper (Watman I ) or centrifuge
S3A P3A
Recycle with P3B
P3B
1) Resuspend in 0.5% SDS, stirO/N @ 4°C
2) Cenlirfuge: 22, UK) x g. 30'. liTQ
3) Wash pellet: 2 x 1 0 ml 0.5% SDS, discard supernatant.
S3B
1) Dry 90-95% in vacuo @ 4()"C.
2) Wash: 2 x 40 ml CHCI3, to remove lipids.
3) Resuspend in buffer UPT
4) Dialyzc v. RO H2O @ 4°C
!) Resuspend in pyridine (stinky!)
2) Dialyze v. 4L AAE, 24 h. @ 4X
3) In cold-room with all buffers cold add dropwise while stimng
1 .5 volumes of n-propanol, followed by
2,5 volumes of n-butanol
4) Filter solution with fast-flow paper (Watman 1 ) or centrifuge
Final Product A
S4B P4B
1) Dry 90-95% in vacuo @ 4()T.
2) Wash: 2 x 40 ml CHCI3, to remove lipids.
3) Resuspend in buffer UPT
4) Dialyze v. RO H2O @ 4°C
Final Product B
Figure 3.7 Purification flow chart for poly(VPGIG) control protein EL.
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The success of the outhned strategy was confirmed by several analytical methods.
SDS-PAGE reiterates the selective solubilization of the n-alkyl alcohols and qualitatively
indicates a final product of homogeneous protein content (Figure 3.8). Qualitatively,
amino acid analysis indicates that obtained protein is the target protein (Table 3.2), a claim
corroborated by both 'H and '^C-NMR spectra, where major resonances are attributed to
residues that constitute 93% of the total composition (Figures 3.9-11).
Figure 3.8 12% SDS-PAGE gel of alcohol-insoluble fraction P3A (lane 1), and combined
final products A and B (lane 2), from the purification protocol developed for EL.
Table 3.2 Theoretical and measured amino acid content of EL.
Residue Theo. n% Meas. n%
Asx 0.4 1.6
Glx 0.8 1.4
Ser 0.4 1.8
Gly 38.4 36.7
His
Arg 0.4 0.9
Thr 0.8 2.4
Ala 0.4 1.0
Pro 18.6 18.2
Tyr 0.1
Val 18.6 16.2
Met 2.1 1.6
He 17.3 16.2
Leu 0.4 1.6
Phe
Lys 1.3 1.6
%VPGI 92.9 87.3
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Figure 3.9 500 MHz 'H-NMR spectrum of EL in formic acid.
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Figure 3.10 Up-field region of 500 MHz '^C-NMR spectrum of EL in formic acid.
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Figure 3. 1 1 Down-field region of 500 MHz ''C-NMR spectrum of EL in formic acid.
It should be mentioned that the above protocol was by no means optimized and was
successful for the Lys2 construct, as described in section 3.3.1 and given by EL in Figure
3. 1 , but may be applicable to other proteins of similar primary sequence (i.e. Lys3
construct).
3.3.3 HUVEC Seeding
Paramount to the eventual application as a biomaterial in vascular prostheses, the
effect of modifications to incorporate amine functionality and subsequent glutaraldehyde
crosslinking on HUVEC adhesion and spreading needed to be evaluated. Key to this
evaluation were two parameters: cell count and cell morphology. The first of these was
ascertained by an assay that relied on the constant genetic content of the cells, and, as
expected for a given genome'^, resulted in nearly superimposeable calibration curves for
HUVECs and UASMCs (Figure 3.12). Cell count alone, however, proved to be a
misleading basis for comparison between substrates, as no information about cellular
activity is obtained.
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Cell Number
Figure 3.12 Cell counting calibration curves for HUVECs and UASMCs FF =
HUVECs(0.0289) - 6.042; F = UASMCs(0.0290) - 1.35]
Illustrating the importance of cell morphology are the results of a 4-hour seeding
experiment, given in Table 3.3. Based on cell count alone, there was a 6.3% and 41.9%
reduction in attached cells on CS5-EL and EL, relative to the control fibronectin (FN)
substrate. However, as visualized in Figure 3.13, cellular morphology is strikingly
different on these substrates, where 89.6 ± 3, 74.4 ± 2.3, and 18.4 ± 10% of attached cells
were spread(ing) on FN, CS5-EL, and EL, respectively. Taken together, in terms of
percent control spreading, differences in substrate adhesion properties are even more
evident (Table 3.3). Furthermore, the 74.4% of attached cells spreading reported here is
consistent with values observed by Panitch (i.e. 67.4 - 70.2%) for HUVECs seeded on
non-crosslinked substrates of the protein from which CS5-EL was derived^ Thus, in
this experiment, HUVEC adhesion to crosslinked CS5-EL was similar to that of FN (P <
0.6) and significantly different from EL (P < 0.04), while combined cell count and
morphology data indicated greater differences between CS5-EL and FN (P < 0.1) and EL
(P < 0.005) (Table 3.3). Therefore, whenever possible, both morphology and cell count
were taken into account in substrate evaluation.
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IgMiM_ggg^^!t o^m 4-hour HUVEC seedingexperin^
CS5-EL %Control
ri> /48U+/30
-
. 100 ±15
CS5-EL 7008 ±1580 P < 0.6 . 80.4 ±19
~ 4346±490 P< 0.001 P<o.n4 n.9±V P<00nm p< 0.005
b)
c)
Figure 3. 13 HUVEC morphology after a 4-hour incubation on fibronectin (a), CS5-EL
(b), and EL (c). Scale bar = 200 |im; same for all photos.
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To investigate whether elastin binding protein (EBP) played a role in HUVEC
adhesion to crosslinked elastin analogs, adherent cells were exposed to chondroitin sulfate
(CS), an N-acetylgalactosamine glycosaminoglycan known to inhibit such binding '6- 19.
Elastin binding protein is a 67 kDa member of three-component, non-integrin elastin
binding receptor expressed on surfaces of cell types that interact with the extracellular
matrix, such as fibroblasts, smooth muscle cells, chondroblasts, leukocytes, endothelial
cells20, and certain cancer cell types. EBP recognizes and binds to similar secondary
secondary structures of non-identical hydrophobic domains on elastin (i.e. VGVAPG),
laminin, and type IV collagen. However, EBP is also a galactoside-binding protein (i.e.
galactolectin) and loses its ability to bind these substrates, in the presence of galactosugars.
In accord with experiments conducted on smooth muscle cells by Hinek et al.'^, four hours
after seeding, half of the culture medium was removed and replaced by PBS alone or by
PBS containing 200 |ig CS (type A from bovine trachea, SIGMA). In contrast to the 50%
reduction in SMC attachment observed by Hinek et al., induced by the addition and 2-hour
incubation of the same concentration of CS, no significant detachment was observed with
HUVECs on any of the test substrates (Figure 3.14).
The lack of HUVEC detachment by CS indicates several conclusions: 1) EBP does
not recognize VPGIG as elastin-like domain; 2) glutaraldehyde crosslinking may block
EBP recognition of VPGIG or otherwise prevent folding into a recognized secondary
conformation, upon crosslinking; and 3) HUVECs may not express EBP at later passages.
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Figure 3.14 Effect of chondroitin sulfate on HUVEC adhesion to test substrates (n=4).
HUVEC adhesion as a function of time was considered, to evaluate conditions
under which substrate specificity may be defined. Cells were seeded on newly prepared
substrates and evaluated, as above, after 1, 2, 4 and 6 hours. The cell count, expressed as
a percent of the control, revealed insignificant differences in substrate specificity at any time
point (Figure 3.15). With morphology taken into account, however, statistically significant
differences were observed at 1, 4, and 6 hours, with the greatest disparity occurring at the
last interval (Figure 3. 16). Comparison of these 4-hour results to those obtained above
with the same cell lot indicates a marked decrease in substrate specificity. Respectively,
77.8% and 1 1.9% control spreading for CS5-EL and EL were observed above, a
difference of 65.9%, compared to the 10.3 % difference (36.8% minus 26.5%) in this
assay. The fact that both of these assays were done at the same passage number (5),
implicates the new substrates as the source of the observed lack of specificity.
Consequently, new cells were obtained and new substrates were prepared.
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Figure 3.15 Percent HUVEC attachment as a function of time (n=3).
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Figure 3.16 Percent control HUVEC spreading as a function of time (n=3).
The effect of bovine serum albumin (BSA) on HUVEC seeding was also
investigated. Prior to this investigation, two successive experiments with new cells (i.e,
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new lot and passages 3 and 4) were conducted to reproduce the 4-hour binding results
presented above: the first used substrates from a new batch that qualitatively proved to not
support adhesion to CSS-EL or EL, after 4 hours; the second used yet another batch of
substrates, yet both substrates supported similar levels of adhesion. Besides substrates,
the only experimental difference was the change in blocking buffer from PBS to HBSS
with 2 mg/ml BSA in each. Consequently, cells were seeded on substrates that had not
been exposed to any BSA at any time, substrates preblocked for up to one hour with BSA-
containing buffer, and substrates that had been both preblocked and seeded with BSA-
containing buffers (2 mg/ml and 1 mg/ml, respectively). The latter of these conditions are
similar to those used by Hubbell et al. and Humphries et al. in similar experiments to
reduce non-specific interactions3-7,2l
Surprisingly, considering that these were substrates prepared in parallel with those
for which no specificity was observed, results similar to those in the initial experiment were
obtained (Figure 3.17). That is, for a given blocking condifion, CS5-EL was moderately
different from FN (P < 0.2 - 0.7), and stafistically disfinct from EL (P < 0.02 - 0.04).
BSA appeared to have no effect on seeding results among the same substrates (FN: P < 0.9
- 1.0, CS5-EL: P < 0.5 - 1.0, EL: P < 0.2 - 1.0). Again, cellular morphology was
strikingly different on these substrates, where 97.5 ± 1.6, 75.0 ± 11, and 18.4 ± 14% of
attached cells were spread(ing) on FN, CS5-EL, and EL, respectively. Why substrate
specificity was reproduced in this experiment with the same cells, at a later passage (5), and
parallel substrates is not enfirely clear. Perhaps the three days of storage at 4°C in PBS
resulted in the removal of surface contaminants, such as residual crystals from the reaction
of Dimedone with GYPs?^, or unreacted GTA or associated reaction products^^. Further
evidence for such claims is presented in the competitive binding results, described below.
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Figure 3.17 Effect of BSA on 4-hour HUVEC seeding (n=3).
To explore whether the binding mechanism was mediated by the adhesion ligand
REDV of the CSS region, competitive binding assays were conducted with soluble
peptides GREDVY and GREVDY. The first of these was used by Massia and Hubbell in
similar studies on REDV-grafted substrates'^, and is comparable to GREDVDY, that proved
to completely inhibit HUVEC adhesion to the base CS5-containing elastin analog from
which CS5-EL was derived ''2. While inhibition was not quantified by Panitch, yet
observed at a peptide concentration of 0.6-0.8 mg/ml, Massia reported a 70 to 90% (0.1-
1 .0 mg/ml) reduction in HUVEC spreading, relative to controls for which 44 ± 4% of cells
spread in the absence of inhibitory peptide. GREVDY was chosen as a scrambled variant
ofGREDVY for control purposes.
Using the protocols of Panitch and Massia as a guide, inhibition studies were
conducted with and without a 30 minute peptide incubation using concentrations of 0.0,
0.3, 0.6, 0.9 and 1.2 mg/ml. Not only were these concentrations comparable to those used
in the model experiments for which inhibition was observed, but were well in excess of the
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receptor/ligand dissociation constant (2.2 x 10"^ M) and sufficient to saturate all of the 5.8 x
10^ receptor sites per cell (i.e. 0.3 mg/ml = 1.4 x 10"^ M» 2.2 x 10"^ M; 0.3 mg = 4.1 x
10-^ moles» 5.8 x 10 moles of sites per 60,000 cells). However, in two separate
experiments, using substrates prepared in parallel with those for which adhesive specificity
was observed and with two cell lots, no significant inhibition was observed at any
concentration with either peptide (data not presented), as determined by cell count alone.
Knowing that morphology needed to be considered, yet lacking sufficient
GREDVY peptide for another experiment, the CS5 region itself was used (SIGMA). Here,
42, 126, and 252 nmoles of each peptide were used with no incubation time, using no
peptide on both CS5-EL and EL, as upper- and lower-boundary controls. The percent of
attached cells spreading with no peptide was 75.8 ± 9 on CS5-EL and 34.6 ± 6 on EL.
In terms of percent control spreading, inhibition was observed with increasing CS5
content, approaching the lower boundary of 27.9 ± 13% of control cells spread on EL
(Figure 3. 1 8). Based on cell count alone, no inhibition was observed at any concentration
(P < 0.6-0.7).
These results indicated that the CS5 domain does indeed play a role in HUVEC
binding to crosslinked CS5-EL, yet, in light of the fact that inhibition was not completely
achieved by soluble peptides and binding was observed on the CS5-free substrate EL,
other binding mechanisms must certainly exist. The possibility of surfaces enriched with
GTA reaction products interfering with the specific interactions was implicated by
preliminary seeding experiments on aminated glass treated with GTA, where HUVEC
spreading was 21.3% lower than on FN (P < 0.2) and only 1 1.6% lower than on CS5-EL
(P < 0.7) (Figure 3.19). Furthermore, spreading was 24.6, 35.0, and 50.1% greater on
GTA than tissue culture plastic (TCP) (P < 0.04), aminated glass (NH2) (P < 0.04), and
glass (P < 0.001), respectively.
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Figure 3.18 Competitive inhibition of HUVECs by CS5 peptide (n=3)
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Figure 3.19 4-hour HUVEC seeding on various substrates (n=3).
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3.3.4 UASMC Seeding
Since smooth muscle cells are also predominant in blood vessels and play a major
role in vessel occlusion, natural or artificial24, seeding experiments were carried out with
umbilical artery smooth muscle cells. As with the HUVEC seeding experiments, both
morphology and cell count were necessarily evaluated (Figure 3.20). In a 4-hour seeding
experiment, UASMC spreading on CS5-EL was the same as FN (P < 1.0) and 12.7 times
greater than EL (P < 0.005) (Table 3.4). The inability of EL to support UASMC
spreading and insignificant detachment with CS (Figure 3.21) both indicate that EBP is not
involved in the binding mechanism. EBP recognition was explored as a function of
conformation by comparing binding to cold-cast films (as the rest) and to coacervate films
(i.e. cast above the LCST from coacervate solufions, prior to crosslinking) both with and
without 800 ^ig CS, a quantity sufficient to shed SMCs from elastin substrates l8(Table
3.5). Again, EBP did not play a role in the binding mechanism.
The CS5 region is implicated in UASMC adhesion. Since GTA reaction products
are expected to be present on both crosslinked substrates, the disparity in UASMC binding
suggests binding via a surface chemistry distinct from that obtained from GTA alone25-26.
The possibility of REDV being a binding domain for SMCs was eliminated by Hubbell et
al. using peptide-derivitized glycophase glass and PEG-modified PET^. In the absence of
a specific ligand, the CS5 domain imparts negative charge (aspartic and glutamic acid),
posifive charge (hisddine and arginine), hydroxyl groups (tyrosine), and amides
(glutamine), thereby distinguishing it chemically from a background of otherwise
hydrophobic residues. Binding via these moieties is supported by the long-standing
recognition that cellular adhesion and proliferation on polymeric substrates is dependent on
surface chemistry (i.e. surface energy and charge)27-3l.
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Figure 3.20 UASMC morphology 1 and 4 hours after seeding on fibronectin (a), CS5-
EL (b), and EL (c). Scale bar = 200 \im; same for all photos.
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Table 3.4 Resu lts from 4-hour UASMC seeding experiment (n=4).
N""^''^'- CS5-EL %ControlS"^™ Attached "X"vs.FN vs. EL Spreadin
FN 5735 ± 860 ~ l [^^3
CS5-EL 6333 ± 1560 P < 0.5 - 99 5 ± 29
EL 2409 ±42 P < 0.001 P < 0.04 7.S±3
"X" vs. FN
P < 1.0
P < 0.001
CS5-EL
vs. EL
00
c
I
j
120
100
80
60
40
20
0
P < 0.03
P<0.8
FN CS5-EL
Substrate
El NoCS
+CS
P<0.7
EL
1-^
Figure 3.21 Effect of chondroitin sulfate (200 ^g, 30 minute incubation) on UASMC
adhesion to test substrates (n=4).
Table 3.5 Effect of 2-hour CS incubation on UASMC adhesion (n=4).
Substrate No CS 800 [ig CS Median % Change F<
FN 11206 ± 1000 10560 ± 920 -5.77 0.2
CS5-EL 8712 ± 1320 7785 ± 17.50 -1 1.0 0.1
CS5-EL Coacervate 9769 + 660 8294 ± 833 -15.1 0.03
EL 4028 ± 550 5188 ± 960 28.8 0.02
EL Coacervate 3603 ± 985 4829 ±1130 34.0 0.2
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3.4 Conclusions / Future Work
The following may be concluded from the above work: 1 ) the expression and
purification of a non-CS5-containing, poly(VPGIG) has been achieved by the
incorporation of short fusions that contain lysine residues, which provide amine
functionality similar to the CS5-containing analogs; 2) in most experiments, HUVEC
adhesion to GTA-crosslinked, CS5-EL was similar to that observed for the positive
control (FN) and significantly different from the negative control (EL); 3) partial inhibition
of adhesion by REDV peptides indicates that the CSS domain plays a role in the HUVEC
binding mechanism; 4) the observations of no substrate specificity in two experiments,
indifference to the addition of CS, and lack of complete competitive implicate GTA and its
associated reaction products in the binding mechanism and indicate that EBP doesn't
mediate adhesion in a perceptible manner; 5) UASMC adhesion to CS5-EL was
significantly greater than to EL and close to that observed for FN; and 6) EBP binding was
not indicated in the UASMC binding mechanism, which, although unknown, most likely
involves nonspecific interactions with the CSS domain.
GTA appears to provide nonspecific binding mechanisms for both cell lines. While
the CSS domain was implicated as a specific ligand for HUVEC adhesion, the CSS domain
also represents a polar, charged region that must certainly alter the surface energy, in the
absence of GTA. Significant is the fact that GTA has been shown to react with the
guanidyl, hydroxyl, and imidazole moieties of arginine, tyrosine and histidine,
respectively32,33^ thereby further altering the surface chemistry to one more amenable to
cellular interaction. Therefore, future experimentation should include means to distinguish
between the wettability characteristics inherent to substrates with and without the CSS
domain, both before and after treatment with GTA.
To eliminate the ambiguities introduced by GTA, alternate crosslinking agents
should be employed. Although GTA proved useful in gaining control of mechanical and
physical properties, and most HUVEC seeding experiments reproduced the behavior of
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uncrosslinkcd analogs, the mixture of reaction products makes full characterization of
crosslinked networks and surfaces very difficult, if not impossible. The next generation of
aminc-spccific crosslmkmg agents might include isocyanates, N-hydroxysuccinimidyl
esters, epoxides, carbonyl diimidazole, p-nitrophenol carbonates, tresylates, or other
electrophilically-activated moieties. These may be used with or without diamine chain
extension agents. As many of these agents are hydrolysable, reactions must be carried out
under dry conditions.
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CHAPTER 4
AN ALTERNATE CROSSLINKING STRATEGY
4.1 Introduction
Glutaraldehyde (GTA) has been used in the role of cross-linking and stabilizing
biomaterials for many years, but, for reasons associated with cytotoxicity, reversibility of
cross-links, and potential for calcification, it is not ideall-4 For these reasons, and those
outlined in the preceding chapters, it was desirable to pursue alternate crosslinking agents.
In contrast to the problems associated with GTA, polyethylene glycol (PEG) is
perhaps one of the most biocompatible polymers with a wide variety of useful properties.
Specifically, PEG is nontoxic, nonimmunogenic^, nonbiodegradable, easily recovered after
implantation^, and is soluble in both organic and aqueous media^. In addition, PEG has
been variously functionalized for the preparation of biologically useful conjugates with
proteins8.9, peptides'^', liposomes' nanoparticles, and others'2,13 Especially important
to the application in vascular grafts is the ability of PEG to reduce thrombogenicity and
both cell and protein adhesion '4. Consequendy, PEG is an ideal choice for a crosslinking
agent, as it will not elicit extraneous cellular binding and is commercially available with
amine-specific, electrophilic functionality.
To evaluate PEG as a crosslinking agent, a commercially available, bis-N-hydroxy
succinimidyl ester of PEG was used. Specifically, a succinimidyl derivative of PEG
propionic acid (SPA-PEG) la was selected to react with an engineered, CS5-containing
elastin analog lb. The feasibility of reacting these macromolecules, having molecular
weights of 3,400 and 36,606 Da for la and lb, respectively, will be assessed in terms of
the stability of the resultant networks, free-amine content, and ability to support endothelial
cell adhesion.
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4.2 Materials and Methods
Methodology and protocols for the biosynthesis, purification and characterization of
lb were presented in detail in Chapter 2. To avoid repetition, only unique methods are
presented here after. SPA-PEG (la) was purchased from Shearwater Polymers, Inc.
(Huntsville, Alabama) and was stored under nitrogen in a vacuum desiccator at 20°C.
Aliquots for crosslinking experiments were weighed in a drybox under argon.
4.2.1 Radiolabelingof lb
Two 1 L cultures were grown in M9 minimal medium containing antibiotics (34
\lg/m\ kanamycin and 34 |ig/ml chloramphenicol, SIGMA), and all essential amino acids.
At an optical density of 0.8/ml, the cultures were induced with IPTG to a final culture
concentration of 1.0 mM. Five minutes later, 1000 |j,Ci of ^H-glycine (DuPont NEN
Research, Boston, MA) was added to the cultures. Radiolabeling was verified by SDS-
PAGE and autoradiography of the resultant, dried gel. The target protein, now
radiolabeled, was purified, as described in Chapter 2 (Section 2.2.4), with a yield 44
mg/L.
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4.2.2 Reaction of la and lb
Protein lb was resuspended at a concentration of 100 mg/ml in cold (4°C) 0.1 M
phosphate buffer, pH 7.0, 7.4, or 8.0. Immediately before use, la was resuspended in
the same, cold phosphate buffer at a concentration of 1 1 1.5 mg/ml. Using the calculated
equivalent weights 1700 g/mol and 9151.5 g/mol for the NHS and amine functionalities,
respectively, reactions tubes having molar ratios of 1:1, 1:2, and 1:3 (amine:NHS) were set
up for each pH value (Table 4. 1). After thorough mixing via pipetting, 150 ^1 aliquots of a
given reaction were spread onto three separate 18 mm diameter glass coverslips. Reactions
were covered and allowed to proceed for 20 hours. Two controls were prepared in parallel:
one without any added PEG and the other with non-functionalized PEG (MW 3,400,
SIGMA). All mixing and incubation steps were carried out at 4°C.
Table 4. 1 Reaction mixtures of la and lb, in microliters
Solution
— — , - -
.
Control (no PEG) Control (no NHS) 1:1 1:2 1:3
la (1 1 1.5 mg/ml) 50 100 150
lb (100 mg/ml) 300 300 300 300 300
phosphate buffer (0. 1 M) 150 100 50
PEG 3400 (1 1 1.5 mg/ml) 150
4.2.3 Solubilization Assays
Reaction tubes were set up, as above, except the protein solution was made with 3
wt.% radiolabeled lb (i.e. 3 + 97 mg/ml). After reacting for 20 hours reactions were
uncovered and allowed to dry. Coated coverslips were then transferred to microwell plates
and hydrated with 1.0 ml of phosphate buffered saline (PBS), pH 7.4, supplemented with
Thimerosal (10 mg/L). Substrates were washed for 24 hours under constant agitation in a
shaker at room temperature. After the time interval, the wash supernatant was removed via
pipetting and combined with 3.0 ml ScintiSafe Plus'^^ 50% (Fisher Scientific, Pittsburgh,
PA), and fresh buffer was added. This process was repeated for 4 consecutive, 24-hour
94
washes. Any remaining material was hydrolyzed with 0.5 ml of 12.0 M HCl, at room
temperature for 48 hours, followed by neutralization to a phenolphthalein endpo.nt with
12.0 M NaOH. Scintillation counting was performed in a Beckman LS 1800 automated
counter. The percent of solubilized protein, at each wash, was determined by dividing the
measured counts of a given wash by the total counts of all washes for that same sample.
Samples were prepared in triplicate and reported values are averages, where error is given
as the standard deviation. Error was propagated through all calculations usmg standard
methods '5-
4.2.4 e-Amine Content
After the 20-hour reaction time, unreacted e-amine content was determined by the
method described in Chapter 2, Section 2.2. 11.
4.2.5 Tissue Culture
Human umbilical vein endothelial cells were cultured, seeded, and counted, as
described in Chapter 3. However, morphological assessment proved to be impractical via
phase-contrast microscopy and photography, since the substrates of interest were opaque.
PEG-CS5 substrates were obtained by spreading 40 |li1 of a reaction mixture, which
consisted of solutions of la and lb in a 1:2 amine to NHS ratio at pH 8.0, on 12 mm
diameter glass coverslips. The PEG substrate was achieved by spreading 40 |il of freshly
prepared la solution (1 1 1.5 mg/ml, 0.1 M phosphate buffer, pH 8.0), on aminated glass
coverslips. Amination of coverslips and other substrates were prepared as outlined in
Chapter 3. All substrates were equilibrated with serum-free growth medium, prior to cell
seeding.
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4.3 Results and Discussion
Crosslinking of lb was investigated as a function of reaction pH and
stoichiometry
.
To assess crosslink efficiency, solubilization of the protein was monitored
as a function of time during four consecutive 24-hour washes with physiological saline
buffer. Protein release into the wash medium during the first wash (i.e. 24-hour solubility)
was found to be dependent on both pH and stoichiometry (Figure 4.2). That is, the
reaction was more effective in insolubilizing lb with increasing pH and NHS content.
With the exception of a 1: 1 reaction stoichiometry at pH 7.0, all reactions were more stable
than either control, where the mixture of PEG 3400 and lb was the most unstable.
3
pH 7.0 1
pH 7.4 1
pH 8.0 1
no PEG no NHS 1:1 1:2
Composition
1:3
Figure 4.2 24-hour solubility of lb after reaction with la, as a function of composition
and pH.
Unlike crosslinking with glutaraldehyde (Chapter 2), where ca 90% of all soluble
material is released in the first two 24-hour washes, the PEG-lb conjugates show
continued protein solubilization in all washes. In general, more protein was released in the
second wash than in the first and progressive solubility was observed up to the point of
acid hydrolysis. In spite of no long-term stability, insolubility, after 96-hours of washing.
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was observed to follow the same trends as with 24-hour solubility: increasing stability with
increasing pH and NHS content (Figure 4.3). These results are consistent with the
expected increase in aminolysis rates with increasing pH, rates that are greater than for
hydrolysis of the activated NHS-ester, at the same pH9.l2,i6,
C
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no PEG no NHS 1:1
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1:2 1:3
Figure 4.3 Insolubility of lb after 4 24-hour washes, as a function of reaction
composition and pH.
Figure 4.4 reveals that the free-amine content decreased with increasing NHS
content. These results indicate that more amine is consumed in the reaction, presumably
via conjugation to PEG, yet insolubility plateaus at a value near 50%, indicating that
additional conjugation does not lead to crosslinks that stabilize the network.
Taken together, these results indicate that a stable network cannot be achieved by
the means employed. As with other chemical reactions, bonds form only when reactive
groups are proximal and in the correct orientation, and, in the case of these
macromonomers, diffusion of reactive groups will decrease with increasing conversion and
accompanying viscosity 1 7. Thus, the reaction rate (aminolysis) is expected to decrease
with increasing conversion, while hydrolysis of NHS remains constant, a condition that
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results in the hydrolysis of all NHS-activated PEG before full protein conjugation, which,
in this case, is crosslinking. Consequently, as supported by
the dissolution of networks, even under the most favorable conditions (i.e. pH 8.0 or
higher), these reactions produced what might be best described as a physical mixture of
high molecular weight complexes of PEG and lb.
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Figure 4.4 e-amine content and insolubility of lb, as a function of NHS stoichiometry
(pH 8.0).
In spite of obtaining highly crosslinked networks, 24-hour solubility results were
used to explore HUVEC seeding. Specifically, PEG-lb gels were formed at pH 8.0 with
a 2-fold molar excess of NHS groups. PEG alone was used as a negative control and was
prepared by conjugation of la to aminated glass. Since the PEG-lb gels were opaque, a
response to culture conditions well above the LCST (Chapter 2), cell morphology was not
taken into consideration and cells were counted four hours after seeding. For comparison,
GTA-crosslinked substrates and fibronectin (FN) were included (Table 4.2). Based on
count alone, 35% more HUVECs attached to PEG-lb than to PEG alone (P < 0.001), a
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value 11% less than that observed for CS5-EL (P < 0.1). As a caveat, in the absence of
morphological evaluation, these results may be misleading. For example, none of the
HUVECs attached to PEG were observed to be spreading while ca 90% were spreading on
FN
Table 4.2 HUVEC count after 4-hour seeding experiment (n=3)
Substrate % Control p<
FN 100 ± 29
CS5-EL 91 ±24 o.l
EL 64 ± 22 0.001
PEG- lb 80 ± 25 0.02
PEG 45±20 0.0001
4.4 Conclusions and Future Perspectives
Several conclusions can be drawn from the above efforts to form PEG-lb
networks: 1) although trends were identified to increase crosslinking efficiency, no
conditions were identified to form networks having persistent, long-term stability; 2)
crosslink efficiency is most likely mitigated by a decreasing aminolysis rate with increasing
reaction viscosity and a constant hydrolysis rate; and 3) while a preliminary HUVEC
seeding experiment showed promising results, cellular morphology should be taken into
account before any strict conclusions are drawn.
These experiments indicate that altemate crosslinking agents and/or conditions
should be explored. In particular, a combination of lower molecular weight ^w-NHS-PEG
and water-free reaction conditions might be considered. Alternately, the CS5 peptide
alone, with an added amine functionality greater than 2, may be explored as a crosslinking
agent for various electrophilically activated PEGs to achieve a non-adherent background
and HUVEC-selective substrate '8.
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